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CHAPTER I 
 
Introduction 
Thesis Overview 
This thesis uncovers a viral protein responsible for the evasion of type I IFN 
signaling during human metapneumovirus (HMPV) infection, and examines the 
repercussions of the lack of type I IFN signaling on the CD8+ T cell (TCD8) response in 
vivo. Chapter I gives background into the HMPV genome and life cycle, mechanisms of 
viral detection and host response, as well as discussing known mechanisms of viral 
innate immune evasion in HMPV and other related viruses. This chapter also explores 
the data related to the TCD8 effector and memory response, impairment of this effector 
function during acute viral lower respiratory infection (LRI), and what is known regarding 
the type I interferon (IFN) contribution to TCD8 response. In chapter II, I present evidence 
that HMPV uses the small hydrophobic (SH) protein to inhibit signal transducers and 
activators of transcription-1 (STAT1) expression and IFN-induced phosphorylation in 
infected cells to block downstream anti-viral signaling. Chapter III focuses on the in vivo 
contributions of type I IFN on HMPV replication and pathogenesis and shows that while 
signaling through the type I IFN receptor (IFNAR) significantly contributes to early viral 
control, it is dispensable for viral clearance. Additionally, type I IFN is shown to 
contribute to disease pathogenesis during HMPV infection. I examine the TCD8 response 
in IFNAR-deficient animals and show that the magnitude and function of this subset of 
cells is impaired in these mice compared to wild-type (WT) mice, despite equal 
programmed death-1 (PD-1) levels and lower overall programmed death ligand-1 (PD-
L1) levels. I also demonstrate that this impairment occurs simultaneously with an 
upregulation of the inhibitory receptor, T-cell immunoglobin domain and mucin domain-3 
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(TIM-3), and a defect in dendritic cell (DC) expansion in the lung. Chapter V is a 
summary of this thesis project, and I also propose future directions for this work. 
.  
Human Metapneumovirus (HMPV) Background 
In 2001, investigators in the Netherlands looking for undiscovered viruses in 
respiratory secretions collected from young children with lower respiratory illness first 
isolated human metapneumovirus (HMPV) (van den Hoogen et al., 2001a). HMPV 
particles grown in cell culture were examined by electron microscopy and shown to 
contain pleiomorphic virus particles with diameters between 150 to 600 nm with spike-
like envelope projections of 13 to 17 nm (Figure 1-2A) (Schildgen et al., 2011). Further 
investigation into the genome using PCR and sequence analysis revealed a single-
stranded, negative-sense RNA genome. The closest relative to HMPV, according to 
sequence homology, is avian metapneumovirus (AMPV), an important respiratory 
pathogen in chickens and turkeys (Cook, 2000). HMPV was classified as the first human 
member of the Metapneumovirus genus, in the subfamily Pneumovirinae of the 
Paramyxoviridae family (Figure 1-1) (van den Hoogen et al., 2002; van den Hoogen et 
al., 2001a).  
A comparison of multiple HMPV gene sequences showed that HMPV diverged 
from an avian metapneumovirus (AMPV-C) between 200-300 years ago (de Graaf et al., 
2008; Yang et al., 2009). Epidemiologic studies showed that this virus has been 
circulating in human populations without being identified for many years. HMPV-specific 
antibodies were found in sera from patients in the 1950s (van den Hoogen et al., 2001a), 
and RT-PCR analysis of lung secretions detected HMPV nucleic acid in specimens from 
1976 (Williams et al., 2004).  
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Figure 1-1. Phylogenetic classification of HMPV within Paramyxoviridae family. 
Evolutionary relationships of members classified in the Paramyxoviridae family were 
predicted from multiple nucleotide sequence alignments of whole viral genomes, and a 
phylogenetic tree was generated using ClustalW program of MegAlign. HMPV (red 
arrow) can be seen in the Pneumovirinae subfamily along with the most closely related 
human virus, RSV (lowest blue arrow). PIV represents the other paramyxoviruses that 
are major contributors to acute viral LRI (three top blue arrows). Adapted from (Nayak et 
al., 2008). 
 
Studies across the globe have shown that HMPV is a leading cause of acute viral 
lower respiratory infection (LRI) in infants and children in every population (Boivin et al., 
2003; Dollner et al., 2004; Ebihara et al., 2004; Esper et al., 2004; Foulongne et al., 
2006; Mackay et al., 2006; McAdam et al., 2004; Mullins et al., 2004; Peiris et al., 2003; 
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van den Hoogen et al., 2003; Williams et al., 2004; Williams et al., 2006a), and 
immunocompromised hosts or persons with underlying respiratory conditions are at 
much higher risk for severe disease (Englund et al., 2006a; Larcher et al., 2005; Madhi 
et al., 2003; Pelletier et al., 2002; Vicente et al., 2004; Williams, 2005; Williams et al., 
2005a). Most cases of HMPV in healthy individuals result in a mild upper airway 
infection, but it is possible to progress to severe lower respiratory tract infections (e.g. 
bronchiolitis and pneumonia) even in non high-risk populations (Brodzinski and Ruddy, 
2009; Williams et al., 2004). Clinical HMPV disease is indistinguishable from closely 
related pathogens like human respiratory syncytial virus (hRSV) and parainfluenza 
viruses (PIV), two more leading causes of viral lower respiratory infection in children 
(Figure 1-1). Infection with HMPV leads to significant inflammation in the respiratory 
tract, as well as necrosis and subsequent sloughing of the bronchiolar epithelium 
(Loughlin and Moscona, 2006). Nonhuman primates and small animal models 
(hamsters, cotton rats, and mice) indicate that replication of HMPV is limited to the upper 
and lower respiratory tract epithelium, showing that, similar to human infection, HMPV 
displays a distinct tissue tropism in these models (Hamelin et al., 2006; Kuiken et al., 
2004; Williams et al., 2005c). 
The genome of HMPV is between 13,280 to 13,378 nucleotides, and contains 8 
genes with 9 open reading frames (Figure 1-2C). The virion is similar to other 
paramyxoviruses, with a viral lipid envelope derived from the plasma membrane of 
infected cells as they bud from the cell surface. The matrix (M) protein of HMPV lines the 
inner membrane of the virion, and studded on the outer leaflet are three integral 
membrane surface glycoproteins, the fusion (F), glycoprotein (G), and short hydrophobic 
(SH) 
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Figure 1-2. HMPV genome structure and virion. (A) Electron micrographs of HMPV were 
imaged on an FEI Morgagni electron microscope (magnification, ×28,000). Protein 
spikes can be observed projecting from virion surface. (B) Model of HMPV virion with F, 
G, and SH proteins studding outer membrane, M protein lining inner membrane, and P, 
N, and L proteins interacting with (-)-sense single-stranded RNA genome. Not pictured 
are the non-structural M2-1 and M2-2 proteins. (C) Representation of the ~13kb long (-)-
sense single stranded RNA genome of HMPV and its encoded gene products. Adapted 
from (Cox et al., 2012) and (www.expasy.org/viralzone, Swiss Institute of Bioinformatics) 
 
proteins (Fig. 1-2). Inside the viral envelope, is a helical ribonucleoprotein (RNAP) 
complex consisting of nucleoprotein (N), phosphoprotein (P), matrix 2 protein (M2), large 
polymerase protein (L), as well as the single-stranded, negative-sense RNA genome 
(Figure 1-2B)(van den Hoogen et al., 2002; van den Hoogen et al., 2001b).  
  
Innate Recognition and Type I IFN Signaling 
Innate detection of pathogens is facilitated through specialized proteins, termed 
pattern recognition receptors (PRRs). These molecules are capable of binding to a 
diverse array of factors specific to microbes, known as pathogen-associated molecular 
patterns (PAMPs). Viral and bacterial nucleic acid, bacterial carbohydrates, 
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peptidoglycans and lipoteichoic acids, bacteria-specific amino acids, lipoproteins as well 
as fungal glucans and chitin all are detected by distinct PRRs (Takeuchi and Akira, 
2010). For paramyxoviruses, like HMPV, viral RNA is sensed in endosomal 
compartments of infected cells by the membrane anchored toll-like receptor 3 (TLR3), 
and in the cytoplasm by the cytoplasmic helicases retinoic acid inducible gene-1 (RIG-I) 
and melanoma differentiation-associated protein 5 (MDA5) (Figure 1-3)(Boehme and 
Compton, 2004; Manuse and Parks, 2010; Matsumoto et al., 2003; Melchjorsen et al., 
2005; Rudd et al., 2005). In innate immune cells, like macrophages and dendritic cells, 
TLR7 and TLR8 are capable of detecting viral nucleic acids in endosomal compartments 
(Figure 1-3)(Goutagny et al., 2010; Manuse et al., 2010). Detection of very closely 
related viruses, even within the same sub-family, has been shown to rely on different 
PRRs (Loo et al., 2008), and, although this phenomenon is poorly understood, evidence 
suggests that it may be related to the secondary structure of viral nucleic acid or the 
presence of triphosphates on the 5’ end of viral genomes (Hornung et al., 2006; 
Pichlmair et al., 2006; Saito et al., 2007; Sumpter et al., 2005). HMPV is detected by 
TLR3 and RIG-I in infected epithelial cells (Banos-Lara Mdel et al., 2013; Bao et al., 
2008b; Dou et al., 2010), as well as by MDA5 and TLR7 in cultured DCs (Goutagny et 
al., 2010).  
Upon sensing viral nucleic acids, PRRs transduce signals through adapter 
molecules. When RIG-I and MDA5 sense PAMPs, the molecule interferon-beta promoter 
stimulator 1 (IPS-1) interacts with TANK-binding kinase 1 (TBK1) and the inhibitor of 
kappa B (IκB) kinase 1 (IKKi) to activate the transcription factors interferon response 
factor 3 and 7 (IRF3 and IRF7) (Kawai et al., 2005). TLR3 signals through the toll-
interleukin receptor (TIR) domain-containing 
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Figure 1-3. Pattern recognition receptors and the type I IFN pathway. PRRs initiate 
signaling pathways converging at the activation of the transcription factors interferon 
IRF3, IRF7 and/or NFκB. This leads to the expression of IFNβ, which signals through the 
type I IFN pathway to produce numerous ISGs. HMPV ssRNA genome and dsRNA 
replication products are sensed by TLR3/7 in the endosomes of infected or innate 
immune cells, and RIG-I and MDA5 in the infected cell cytoplasm to trigger IFN 
production. Adapted from (Bowie and Unterholzner, 2008). 
 
 
adaptor-inducing IFN-β (TRIF) and tumor necrosis factor (TNF) receptor-associated 
factor 3 (TRAF3), also utilizing TBK1 and IKKi to activate IRF3 and IRF7 (Kawai and 
Akira, 2010; Oshiumi et al., 2003; Yamamoto et al., 2003). In TLR7 signaling, the 
myeloid differentiation primary response protein (MyD88) along with interleukin-1 
receptor-associated kinase 4 (IRAK4) and TNF receptor-associated factor 6 (TRAF6) 
work together to activate IRF7 (Ito et al., 2002; Schoenemeyer et al., 2005).  
Both type I and II IFN signaling rely on STAT1 as a crucial component of their 
signaling pathway. After ligation of IFNα or β to the type I IFN receptor, Janus kinases 
(Tyk2/JAK1) associated with the receptor cytoplasmic tail to phosphorylate STAT1 
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(Tyr701) and STAT2 (Tyr689), which together with interferon response factor 9 (IRF9) 
form a transcription factor, called interferon stimulated gene factor 3 (ISGF3). ISGF3 is 
capable of binding to promoter elements for cytokines, chemokines and peptides 
associated with the anti-viral response (Figure 1-3)(Platanias, 2005). For type II IFN 
signaling, IFNγ binds to the interferon gamma receptor (IFNGR) inducing 
phosphorylation of STAT1 (Tyr701) by other Janus kinases (JAK1/JAK2) resulting in a 
homodimer of STAT1 that acts as a transcription factor to bind to the gamma activating 
sequence (GAS), a promoter for many of the same anti-viral molecules induced by type I 
signaling (Platanias, 2005). Indeed, type I and II IFN signaling induce an overlapping set 
of antiviral molecules, and act in combination to produce a cellular antiviral response 
(Decker et al., 2005; Pestka et al., 2004; Schroder et al., 2004). These signals also 
prime an efficient adaptive immune response, which will be discussed in detail later 
(Havenar-Daughton et al., 2006; Kolumam et al., 2005a; Le Bon and Tough, 2008; Luft 
et al., 1998). The work in this thesis clearly shows that type I IFN signals can contribute 
to disease pathogenesis (Gautier et al., 2005; Goritzka et al., 2014; Rudd et al., 2007). 
The further implications of type I IFN signaling in HMPV infection will be explored in 
chapters III and IV. 
 
Evasion of type I IFN signaling by Paramyxovirus 
 The type I IFN response exerts a strong evolutionary pressure in the battle 
between pathogen and host, but viruses are not helpless in this fight. They have evolved 
varied and effective mechanisms of evading the innate immune response through their 
viral gene products (Table 1-1). Viruses related to HMPV, such as RSV and PIV, encode 
one of two classes of proteins responsible for targeting and inhibiting signaling through 
the innate immune pathways. RSV encodes the nonstructural-1 (NS1) and nonstructural-
2 (NS2) proteins and the PIV genome contains an alternative reading frame of the P/C/V 
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gene that encodes multiple immune evasion proteins. These proteins specifically inhibit 
aspects of innate immunity in a variety of ways (Andrejeva et al., 2004; Childs et al., 
2012; Gainey et al., 2008; Lo et al., 2005). Interestingly, the HMPV genome contains no 
analogous open reading frames to any of these previously identified as innate immune 
antagonists (Piyaratna et al., 2011; van den Hoogen et al., 2002). This led us to 
hypothesize that HMPV is using a viral protein in a unique way to evade the type I IFN 
signaling pathway.  
 
Paramyxoviruses other than HMPV 
Expression of type I IFNs during paramyxovirus infection is dependent on 
recognition of viral nucleic acids by the cytosolic RNA helicases, RIG-I and MDA5, as 
well signaling events through adaptor molecules, such as interferon-β promotor 
stimulator-1 (IPS-1), TNF receptor-associated factor (TRAF) and IRF proteins. Viruses 
have evolved mechanisms to target virtually every step in this process. Parainfluenza, 
measles, Sendai and Nipah viruses all encode a V protein, which is capable of binding to 
MDA5 and blocking the detection of viral nucleic acids (Andrejeva et al., 2004; Childs et 
al., 2009; He et al., 2002; Poole et al., 2002). Instead, the NS2 protein of RSV has been 
shown to bind to RIG-I blocking the downstream phosphorylation of IRF3 and the 
expression of type I IFNs (Ling et al., 2009). An outstanding question in the field is why 
viruses target one of these RNA helicases over the other, but it is likely related to 
differences in how the viral nucleic acid of individual viruses are detected by PRRs.  
STAT proteins are often targeted by viruses from the Paramyxoviridae family to 
evade innate immune signaling through various mechanisms (Caignard et al., 2007; 
Takeuchi et al., 2003). The V protein from PIV5 and mumps virus and the NS2 protein 
from RSV target STAT proteins for proteosomal degradation (Didcock et al., 1999a, b; 
Kubota et al., 2001; Ramaswamy et al., 2004). Measles virus, by contrast, does not 
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affect STAT protein expression, but uses the V protein to prevent STAT phosphorylation 
and therefore block formation of the interfereon stimulated gene factor-3 (ISGF3) 
transcription factor and subsequent translocation to the nucleus (Takeuchi et al., 2003). 
The Nipah virus V protein binds to STAT proteins to induce high-molecular-weight 
complexes, which blocks type I IFN signaling (Rodriguez et al., 2004; Rodriguez et al., 
2002). The wide variety of mechanisms employed in the inhibition of type I IFN signaling 
indicates that this pathway presents a substantial evolutionary pressure on the life cycle 
of Paramyxovirus, and thus I hypothesized that a similar evasion mechanism exists for 
HMPV. 
Virus Viral 
Protein 
Target 
Protein 
Outcome Reference 
PIV-1 C STAT1 Inhibits nuclear 
translocation 
(Van Cleve et al., 2006) 
PIV-2 V STAT1, 
STAT2 
Degradation of 
protein 
(Andrejeva et al., 2002) 
PIV-3 V and D STAT2 Block formation of 
ISGF3 
(Young et al., 2000) 
RSV NS1 and 
NS2 
STAT1, 
STAT2 
Block nuclear 
translocation and 
phosphorylation 
(Jie et al., 2011) 
 NS2 STAT2 Degradation of 
protein 
(Ramaswamy et al., 2004; 
Ramaswamy et al., 2006) 
HMPV SH STAT1 Decreased 
expression and 
phosphorylation 
(Hastings et al., unpublished)  
Table 1-1. Summary of type I IFN evasion by human paramyxoviruses. Multiple 
mechanisms of type I IFN evasion have been described in the Paramyxoviridae family, 
which target the STAT proteins. 
 
 
HMPV Innate Immune Evasion 
As mentioned previously, HMPV does not encode for the known innate immune 
antagonists encoded by related viruses, but evidence exists that implicates HMPV gene 
products in this phenomenon. The phosphoprotein (P), M2-2, the glycoprotein (G) and 
the SH protein have all been suggested to play a role in the evasion of innate immune 
responses to HMPV. One group showed a differential ability for the A and B subgroups 
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of HMPV to induce type I IFN, and suggested that the P protein of the B1 subgroup of 
HMPV was able to prevent RIG-I activation and the production of IFNs (Goutagny et al., 
2010). It is unclear whether this inhibition was due to a direct interaction with host innate 
immune sensors, or if the P protein’s interactions with viral RNA or its effect on the 
translation of other viral proteins was responsible for this phenotype. The M2-2 protein is 
not necessary for viral growth (Biacchesi et al., 2005; Buchholz et al., 2005), but data 
suggest that it might target the important PRR mediator mitochondrial antiviral-signaling 
protein (MAVS) to prevent innate immune signals by the cytoplasmic helicases RIG-I 
and MDA5 (Ren et al., 2012). HMPV G protein has been suggested to play a role in the 
direct inhibition of RIG-I through interactions between the caspase activation and 
recruitment domain (CARD) of the PRRs N-terminus (Bao et al., 2013), leading to higher 
levels of inflammatory cytokine production in cells infected with HMPV lacking the G 
protein. Evidence will be presented in chapter II of this thesis to implicate the SH protein 
in the evasion of type I IFN through inhibition of STAT1 phosphorylation, and other 
groups have shown that SH may downregulate TNFα signaling in a cell culture system 
(Bao et al., 2008a). STAT1 is not a component of canonical TNF signaling, but has been 
shown to serve as a regulator of activated tumor necrosis factor alpha (TNF-alpha) 
receptor 1 (TNFR1) recruitment of TNFR1-associated death domain protein (TRADD) 
and subsequent signaling events (Wang et al., 2000). 
  
CD8+ T Cells – Activation and Function during Viral Infection 
During viral and intracellular bacterial infections, as well as in the response to 
cancer, TCD8 cells are thought to be primarily responsible for the generation of a 
protective immune response. These cells are capable of responding to pathogens with 
clonal expansion and differentiation into a cytotoxic effector cell phenotype. Effector TCD8 
cells home along a chemokine gradient to infected or tumor tissue and express 
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molecules capable of clearing infection and eliminating cancerous cells. The activation, 
differentiation and progression of TCD8 to a memory phenotype, capable of responding 
quickly to future immunological insult, is tightly controlled by a symphony of innate 
inflammatory responses and antigen presenting cells (APCs) to respond in an 
appropriate way without damaging host tissues. After initial contact with the pathogen, 
memory TCD8 cells are generated, and can be rapidly reactivated and expand with 
exposure to a previously encountered pathogen. 
During viral infection, the TCD8 response begins with rapid clonal expansion, 
leading to T cell differentiation into an effector phenotype. As the pathogen is cleared, T 
cells begin to contract via apoptosis of effector TCD8 cells, and long-lived memory cells 
are formed (Figure 1-5A) (Kaech and Wherry, 2007). Specialized APCs scavenge and 
engulf antigen from the site of infection and subsequently extravasate to secondary 
lymphoid organs like the spleen and draining lymph nodes where they encounter naïve 
TCD8 cells and prime them for response to the invading pathogen (Zhang and Bevan, 
2011).  These pathogen-specific T cells begin as around 100-200 naïve precursors that 
quickly expand 104- to 105-fold (Blattman et al., 2002).  Dendritic cells (DCs) are a 
subset of APC that express high levels of co-stimulatory ligands and are able to 
efficiently migrate to secondary lymphoid tissues to interact with naïve TCD8. During 
acute respiratory viral infection, subsets of DCs, specifically those expressing CD103 on 
the cell surface, have a greater innate ability to prime an anti-viral TCD8 response 
(GeurtsvanKessel and Lambrecht, 2008; Hao et al., 2008; Kim and Braciale, 2009).  
More recently, it has been shown that specific DC subsets play specialized roles 
in the overall development of protective immunity. Kim et al showed that during influenza 
virus infection, CD103+ DCs were particularly important for the TCD8 effector phenotype, 
while interaction with CD11b+ DCs primed these cells to possess characteristics of  
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Figure 1-4. TCD8 recognition of infected cells and effector mechanisms. Infection of cells 
triggers the activation of immunoproteasome, which cleaves viral proteins into smaller 
fragments. These fragments are imported into the ER by the TAP protein, where further 
processing occurs and viral peptides 8-10 amino acids in length are loaded into MHC 
class I molecules for presentation at the cell surface. Upon recognition of MHC:peptide 
complex (Ag), TCD8 release the effector molecules perforin and granzyme as well as the 
cytokine IFNγ leading to the production of anti-viral proteins and apoptosis of infected 
cells. Adapted from (Nesmiyanov et al.) 
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central memory CD8+ T cells (Kim et al., 2014). Under inflammatory conditions, DCs that 
have endocytosed viral antigen are capable of cross-presenting foreign peptides of 8-10 
amino acids loaded in MHC class I molecules, and express these peptide:MHC 
complexes (Ag) on their cell surface (Belz et al., 2002; Helft et al., 2012). Once this 
activated cell reaches the secondary lymphoid organ naïve TCD8 can recognize the 
pathogen-specific Ag via the T cell receptor (TCR) to trigger activation and proliferation.  
This initial interaction between TCD8 and DC is not sufficient to induce a response, 
and a second signal is required. CD28 molecules on the T cell surface interact with the 
costimulatory ligands CD80 and CD86 on APC, inducing signaling in the TCD8 through 
the phosphoinositide 3-kinase (PI3K)-protein kinase B (Akt)-mammalian target of 
Rapamycin (mTOR) pathway, which supplements TCR-mediated signaling (Salmond et 
al., 2009). Without this second signal, T cells become unresponsive, a state termed 
anergy. This phenomenon plays a crucial role in the maintenance of peripheral tolerance 
and the prevention of autoimmunity (Powell and Delgoffe, 2010). PD-1 and CTLA-4, two 
inhibitory T cell receptors discussed later, are also implicated in the active induction of 
peripheral tolerance through a T cell-intrinsic mechanism (Probst et al., 2005). Finally, 
inflammatory cytokines are also important in the differentiation and expansion of TCD8.  
When naïve TCD8 become activated, they migrate along a chemokine gradient to 
sites of infection (Pachynski et al., 1998; Potsch et al., 1999; Stein et al., 2000). Infected 
epithelial cells can act as APCs by expressing Ag in the context of MHC class I 
molecules on their surface and making them visible to a pathogen-specific T cell (Figure 
1-4) (Rimmelzwaan et al., 2004). Effector TCD8 express cytotoxic molecules (perforin and 
granzymes), and store them in lytic granules that are released upon recognition of Ag to 
kill the infected cell. Perforin is capable of forming pores in the membranes of infected 
cells to allow the entrance of other effector molecules (Sad et al., 1996). One important 
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group of these effectors are granzymes, serine-proteases that activate cytoplasmic 
caspases to induce apoptosis (Hoves et al., 2010). Interferon gamma (IFNγ) and tumor 
necrosis factor alpha (TNFα) are also highly expressed and secreted by TCD8 to recruit or 
activate other immune cells, and activate anti-viral pathways in infected cells to inhibit 
viral replication and induce inflammation. The most efficient protective antiviral immunity 
is provided by TCD8 that are capable of secreting IFNγ, TNF and IL-2 and are capable of 
rapidly proliferating upon Ag exposure (Betts et al., 2006). These cells are crucial in the 
clearance of acute respiratory viral infection through the direct lysis of infected cells 
(Bruder et al., 2006). 
During their development in the primary response, TCD8 differentiate into either 
effector or memory phenotype based on signals from APCs and the infectious milieu 
(Gerlach et al., 2010a). A few models exist for how a response, beginning with a small 
number of naïve precursor cells, expands into the diverse array of phenotypically distinct 
T cell subsets observed during infection. The earliest theory was that innate genetic 
differences are intrinsic within the naïve cell population leading to differentiation during 
infection, but evidence now exists that shows that a single naïve TCD8 has the potential to 
progress to a myriad of differentiated phenotypes (Gerlach et al., 2010b; Stemberger et 
al., 2007). The decreasing-potential model, the signal-strength model, and the 
asymmetric cell fate model are centered around the idea that cell fate is determined by 
the specific signals received during infection (Kaech and Cui, 2012). The decreasing-
potential model posits that repetitive antigen or cytokine stimulation can drive T cells 
away from a memory state and to an effector phenotype (Ahmed and Gray, 1996). When 
a DC vaccination approach is used, the inflammatory cytokine response is limited and 
this has been shown to selectively drive memory differentiation (Badovinac et al., 2005).  
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Figure 1-5. TCD8 fates during acute viral infection. (A) During the expansion phase, Ag-
specific TCD8 rapidly proliferate (expansion phase) and differentiate into short-lived 
cytotoxic T lymphocytes that kill infected cells. During the contraction phase, most 
effector T cells die, but 5–10% survive and mature into memory TCD8 capable of rapid 
reactivation upon reinfection. (B) At the peak of the TCD8 response multiple subsets of T 
cells arise. Terminal effector T cells (blue) are KLRG1hiIL‑7RlowCD27low and memory 
precursor cells (shown in red) are KLRG1lowIL‑7RhiCD27hi. The transcription factors 
important for these distinct subsets are Eomes, Bcl-6 and ID3 for memory development, 
and T-bet, Blimp-1 and ID2 drive effector differentiation. Adapted from (Kaech and Cui, 
2012). 
 
In studies with varying degrees of inflammation, but a constant level of Ag, a relationship 
between the balance of effector and memory phenotypes and inflammatory 
signals became clear (Badovinac et al., 2004; D'Souza and Hedrick, 2006). The signal 
strength model supports the idea that instead of the frequency of the antigen and 
cytokine interactions, the intensity of the stimulation controls cell fate; the previously 
discussed experiments were unable to distinguish between these two models 
(Lanzavecchia and Sallusto, 2002). 
Evidence shows that this differentiation can begin at the first cell division after 
activation due to the inheritance of the immunological synapse in one daughter cell 
(Chang et al., 2007) and the unequal distribution of the transcription factor T-bet (Chang 
et al., 2011). The asymmetric fate model holds that this unbalanced division of signaling 
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molecules important for effector functions leads to the development of divergent 
functions. T-bet drives effector TCD8 differentiation (Naito et al., 2011), and even small 
increases favor an effector phenotype (Joshi et al., 2007). The majority of cells will 
become short-lived effector cells (SLEC), which express high levels of cytotoxic 
molecules, and undergo apoptosis after clearance of infection, however a small 
percentage of these cells become memory precursor effector cells (MPEC) which when 
given the correct signals become long-lived memory cells in the host (Figure 1-2B) 
(Parish and Kaech, 2009). These final three models all explain experimental evidence 
well, and likely are not mutually exclusive. 
TCR stimulation and inflammatory cytokine signaling (i.e. TNF and IFN) reinforce 
SLEC development. Signaling strength through the TCR is directly related to the loss of 
memory cell potential, and the terminal differentiation to an effector phenotype (Ahmed 
and Gray, 1996). The TCR uses mammalian target of rapamycin (mTOR) to activate the 
transcription factor IRF4 leading to the expression of effector molecules, shown to be 
important for the TCD8 response to influenza (Yao et al., 2013). The further induction of T-
bet is potentiated by IL-12, produced by activated APCs (Joshi et al., 2007), through the 
Forkhead box protein O1 (Foxo-1)-dependent mTOR pathway (Rao et al., 2010), and IL-
2 further drives effector differentiation and acquisition of cytolytic functions through 
Blimp-1 (Malek and Castro, 2010; Pipkin et al., 2010) Blimp-1 signaling during acute 
infection leads to the specific upregulation of the effector molecules granzyme B and 
perforin (Rutishauser et al., 2009), supports TCD8 migration to the lung through 
expression of CCR5 (Kallies et al., 2009), and increases expression of T-bet and ID2, 
both associated with effector functions. It can also inhibit factors that promote memory 
development, such as T-cell factor 1 (Tcf-1) and Eomesodermin (Eomes) (Kaech and 
Cui, 2012). Runt-related transcription factor 3 (Runx3), neurogenic locus notch homolog 
protein 2 (Notch2) and wingless-related integration (Wnt) are all involved  
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Figure 1-6. TCD8 memory differentiation. Naïve T cells progressively differentiate 
according to their exposure to Ag and specific cytokines. Three major circulating subsets 
exist — stem cell memory T (TSCM), central memory T (TCM) and effector memory T (TEM) 
cells —, and two subsets are found mostly in peripheral tissue — effector T (TEff) and 
tissue-resident (TRM) cells. Adapted from (Farber et al., 2014). 
 
in the promotion of effector TCD8 functions (Cruz-Guilloty et al., 2009; Jeannet et al., 
2010; Maekawa et al., 2008; Zhou et al., 2010). Type I IFN also plays an important role 
in the fate of naïve T cells (Xiao et al., 2009), which will be discussed further in the final 
section of this introduction. 
SLEC are crucially important in the host response to pathogens, and have 
greater cytolytic function compared to MPEC (Lefrancois and Obar, 2010), but they are 
short lived and cannot provide future immunity. A subset of MPECs, by contrast, go on 
to make up long-lasting memory T cells, capable of responding quickly to infection and 
acquiring effector functions (Jameson and Masopust, 2009). While Blimp-1 expression 
encourages an SLEC phenotype, the expression of B-cell lymphoma 6 (Bcl-6) leads to 
memory differentiation (Crotty et al., 2010; Ichii et al., 2007; Ichii et al., 2002; Pepper et 
al., 2011). Costimulatory receptors cluster of differentiation 28 (CD28), cluster of 
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differentiation 40 (CD40), 4-1BB, inducible T-cell costimulator (ICOS) and OX40 also 
impact the balance of the effector and memory T cell populations (Figure 1-8). OX40 
promotes MPEC to memory cell transition (Mousavi et al., 2008), 4-1BB has been shown 
in influenza infection to impact memory response (Bertram et al., 2002), and together 
these two molecules are crucial for re-expansion during secondary influenza challenge 
(Hendriks et al., 2005). As mentioned before, when Ag is held constant increasing 
inflammatory signals, from either IL-12 or IFN can bias away from the memory response 
through T-bet expression (Cui et al., 2009; Joshi et al., 2007).   
In order to persist for extended periods in the host, fully differentiated memory 
TCD8 rely on IL-7 and IL-15 to provide necessary survival signals and do not need TCR 
signaling. (Hand et al., 2007; Sun et al., 2006; Surh et al., 2006). Memory TCD8 have so 
far been classified into three groups: effector memory (TEM) cells and central memory 
(TCM) cells are often referred to as circulating memory cells (Sallusto et al., 1999), and 
another subset that is localized to peripheral sites, called tissue-resident memory (TRM) 
cells (Figure 1-6).  TEM cells recirculate through the host circulatory system, and lack the 
lymph node homing receptors cluster of differentiation 62 ligand (CD62L) and C-C 
chemokine receptor type 7 (CCR7), thus remaining outside of the lymphatic system. TEM 
cells have been shown to progressively lose the ability to home to peripheral tissues due 
to loss of chemokine receptors (Bedoui and Gebhardt, 2011; Masopust et al., 2010). 
This was linked to loss of antigen stimulation in these cells (Bedoui and Gebhardt, 2011; 
Yang et al., 2011), and repeated boosting of memory TCD8 pushes more of TEM to the 
effector-like phenotype (Nolz and Harty, 2011; Wirth et al., 2010).  Persisting in the 
lymph node, TCM cells (CD62Lhi, CCR7hi), can mount a robust secondary responses and 
establish effector functions upon restimulation (Kaech and Wherry, 2007).  The 
extravasation of these memory T cells from the lymphatics (TCM) or from circulation (TEM) 
to the site of infection is dependent on the chemokine receptor CXCR3, which increases 
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in expression as memory cells mature, and also its ligands monokine-induced by γ IFN 
(MIG) (CXCL9), IFNγ-induced protein 10 (IP-10) (CXCL10), and IFN-inducible T-cell α 
chemoattractant (I-TAC) (CXCL11) (Groom and Luster, 2011a, b; Hikono et al., 2007). 
TEM cells can persist in the lung for several months after influenza or Sendai virus 
infections (Hogan et al., 2002; Hogan et al., 2001), and it appears that the lung 
microenvironment, independent of Ag, is able to maintain these cells in an activated 
state (Kohlmeier et al., 2007).  TCM expressing CCR5 also protect against influenza 
challenge (Kohlmeier et al., 2008) and can reacquire effector functions through IFN 
signaling (Kohlmeier et al., 2010). 
TRM cells (CD103hi, CD69hi, CD62Llo, CD27lo) are a newly described subset of 
memory T cells that remain at the site of initial infection and are capable of quickly 
responding in those tissues (Kaech and Wherry, 2007; Shin and Iwasaki, 2013). They 
are thought to arise from a common memory precursor as circulating memory (Mackay 
et al., 2013), and because of their proximity to sites of pathogen invasion, these cells 
play an especially important role in the immediate response to virus and the recruitment 
of circulating memory T cells (Sathaliyawala et al., 2013; Schenkel and Masopust, 2014; 
Wu et al., 2014).  Survival of TRM in the tissue is maintained by interferon-induced 
transmembrane protein 3 (IFITM3) expression (Wakim et al., 2013), and vaccination 
approaches targeting these cells in the lung for influenza virus have proven very 
effective at eliciting protective immunity (Wakim et al., 2015). The expression of CD69L 
is necessary for the ability for TRM to reside in mucosal tissues (Lee et al., 2011; Mackay 
et al., 2013). During the response at peripheral sites of infection, circulating memory 
cells downregulate the transcription factor Krüppel-like Factor 2 (KLF2), which relieves 
suppression of CD69L and allows for migration (Casey et al., 2012; Skon et al., 2013). 
Recent work has also shown that the expression of CD103 by TRM is a crucial 
component in the maintenance of these cells in peripheral tissue, and the T-bet-
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dependent expression of this molecule is driven by transforming growth factor beta 
(TGFβ) production from CD4+ T cells (TCD4)(Laidlaw et al., 2014). Both circulating and 
tissue-resident TCD8 have shown to be highly effective at host control of previously 
encountered pathogens (Slutter et al., 2013; Wu et al., 2014), and the TCD4 response is 
also crucial for a heterosubtypic response (McKinstry et al., 2012; Teijaro et al., 2011), 
defined by cross-protection from serotypes other than the vaccination strain (Nguyen et 
al., 2007). 
Both the adaptive and innate immune responses orchestrate an effective immune 
response to viral infection, and the data presented in this section highlights that 
depending on the signals received from the pathogen and from the infectious 
environment, TCD8 of diverse effector and memory functions arise. As outlined earlier, 
viruses have evolved mechanisms to evade innate immunity, and the work presented in 
this thesis seeks to elucidate the outcomes of this disruption. It is important to keep in 
mind that since the immune response is so finely balanced, even a slight perturbation of 
immune response by the pathogen has the potential to have profound consequences. 
The host also encodes overlapping mechanisms of immune surveillance and response, 
as well as fine-tuning to protect sensitive tissues, and pathogens are well suited to find 
and exploit these potential niches in which host pathways can be used for their 
advantage.  
 
CD8+ T Cells – Impairment during Acute Respiratory Virus Infection 
 While it is clear that the TCD8 response to respiratory viruses is crucial for 
clearance, recent data suggests that lung virus-specific TCD8 are impaired in their effector 
functions. While examining the functional ability of RSV-specific lung TCD8 during an 
infection in a mouse model, researchers showed that only a small proportion of these 
cells were able to respond to antigenic stimulation by expressing IFNγ (Chang and 
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Braciale, 2002; Lukens et al., 2006), although spleen and lymph node resident RSV-
specific TCD8 functioned normally. In subsequent studies, both PIV-5, influenza and 
vaccinia virus (VACV) resulted in similar T cell impairment during infection (Gray et al., 
2005; Vallbracht et al., 2006). The ability for these T cells to make TNF and lyse infected 
cells was also greatly reduced due to a lessened ability to mobilize lytic granules with 
lower granzyme B content (Vallbracht et al., 2006). Work by Erickson et al showed that 
the mechanism behind this exhaustion was primarily driven by the inhibitory T cell 
receptor PD-1 (Erickson et al., 2012), with minor contributions from other inhibitory 
receptors (Erickson et al., 2014a).   
Despite the acute nature of these respiratory viral infections, this impairment of 
TCD8 and the inhibitory markers associated, resembles a unique state of TCD8 
differentiation that occurs during chronic infections and cancer termed T cell exhaustion.  
Exhausted TCD8 have reduced effector functions, highly express numerous inhibitory 
receptors and possess a distinct transcriptional profile distinct from other TCD8 subsets.  
The first description of this cell type was in mice chronically infected with LCMV 
(Gallimore et al., 1998), and this phenomenon is now well studied in the context of 
chronic viral, bacterial and parasitic infections of mice and humans as well as cancer 
(Virgin et al., 2009). During chronic LCMV clone-13 infection of mice, TCD8 progressively 
lose effector functions in a manner that is both viral-load- and time-dependent (Wherry et 
al., 2003) (Blackburn et al., 2009; Mueller and Ahmed, 2009). IL-2 production, 
proliferative capacity and cytolytic killing are the first functions lost during exhaustion, 
followed by loss of TNF production, and then IFNγ (Wherry et al., 2003). Finally, 
terminally exhausted TCD8 can undergo apoptosis (Wherry et al., 2007) (Figure 1-7). This 
apoptosis is related to the downregulation of the IL-7 receptor, which leads to reduced 
expression of anti-apoptotic molecule B cell leukemia/lymphoma 2 (Bcl-2) (Lang et al., 
2005), as well as signaling by PD-1 (Dong et al., 2002; Shi et al., 2011). Viruses can 
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escape detection by T cells by mutating important amino acids within viral TCD8 epitopes, 
and this results in down-regulation of inhibitory receptors by TCD8 no longer recognizing 
antigen (Ag) (Blattman et al., 2009).    
 Exhausted TCD8 appear to comprise a unique subset of T cells, and their 
transcriptional profile is distinctly different from that of effector or memory TCD8 (Doering 
et al., 2012; Wherry et al., 2007). Unlike memory cells, which express IL-7R and IL-15R, 
exhausted TCD8 become dependent on TCR signaling for survival, in a phenomenon 
termed ‘Ag addiction’ (Shin and Wherry, 2007). Experimental evidence in the LCMV 
model shows that the loss of virus-specific TCD8 upon Ag withdrawal or viral mutation 
does not restart memory T cell development (Wherry et al., 2004) unless it occurs very 
early (Blattman et al., 2009), further showing that T cell exhaustion is a uniquely 
differentiated state (Angelosanto et al., 2012). (Utzschneider et al., 2013). This impaired 
state appears to be partially controlled by epigenetic modifications of genes since TCR 
signaling drives demethylation of the Pdcd1 promoter, which encodes the inhibitory 
receptor PD-1. This phenomenon primes the exhausted T cell for rapid re-expression of 
PD-1 under inflammatory conditions (Youngblood et al., 2011).  Exhaustion also appears 
to be wholly unique from the two other well-known states of T cell dysfunction, anergy 
and senescence. Gene expression patterns in these three states are different between 
all groups, and regulation of the T cell impairment is specific to each (Jackson et al., 
2013; Schwartz, 2003; Teague et al., 2008; Wherry et al., 2007).   
 
Inhibitory Pathways During Acute Infection 
 An over-exuberant response to pathogens can lead to damage to sensitive 
tissues, and the immune system has evolved regulatory mechanisms to prevent these 
unintended consequences. Cell surface inhibitory receptors, soluble factors and 
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Figure 1-7. Exhaustion of TCD8 cells. Functional memory TCD8 are generated upon 
clearance of acute infection, but during both chronic and acute respiratory virus infection, 
Ag persistence and continued inflammation leads to the progressive loss of effector 
functions, due to the actions of inhibitory receptors such as PD-1.  Adapted from 
(Wherry, 2011). 
 
specialized immunoregulatory cells (i.e., CD4+ regulatory T cells) all work in concert to 
finely tune host response.  Inhibitory receptors, in particular, have been shown to play a 
key role in inducing self-tolerance and preventing autoimmunity (Kasagi et al., 2011), as 
well as in the down-regulation of T cell responses during chronic viral infection (Blattman 
et al., 2003; Trautmann et al., 2006; Wherry et al., 2003; Zhang et al., 2007) and are 
relatively well studied in that context. Recent data suggests that these receptors also are 
upregulated during acute viral infection (Barber et al., 2006; Lafon et al., 2008; Phares et 
al., 2009; Zelinskyy et al., 2011), and they serve a particularly important role during 
 25 
acute viral LRI (Chang et al., 2004; Erickson et al., 2012; Sharma et al., 2011; Workman 
et al., 2004).  
Programmed Cell Death-1 and Its Ligands 
 PD-1 (CD279) was discovered in studies of cells undergoing apoptosis and is a 
CD28-family member (Ishida et al., 1992). A 288 amino acid type I transmembrane 
glycoprotein, containing a single IgV-like domain, PD-1 is expressed on activated T cells, 
B cells and monocytes (Agata et al., 1996b). This inhibitory receptor exerts inhibitory 
effects by directly antagonizing TCR stimulation. Ligation of PD-1 results in recruitment 
of src homology 2 domain-containing tyrosine phosphatase 2 (SHP-2) to a C-terminal 
tyrosine residue on the cytoplasmic tail, termed an immunoreceptor tyrosine-based 
switch motif (ITSM). SHP-2 dephosphorylates the TCR-associated proteins	  cluster of 
differentiation 3 ζ (CD3ζ) and	  zeta-chain associated protein kinase 70kDa  (ZAP70), 
blocking activation of PI3K and inhibiting the PI3K/Akt pathway (Figure 1-4) (Chemnitz et 
al., 2004a; Okazaki et al., 2001; Pages et al., 1994; Sheppard et al., 2004). PD-1 
signaling subsequently inhibits production of the pro-survival factor B-cell lymphoma-
extra large (Bcl-xL) (Chemnitz et al., 2004b), and transcription factors, T-bet and Eomes, 
associated with effector and memory function, respectively (Nurieva et al., 2006).  
The expression of PD-1 on TCD8 cells is upregulated by Ag exposure. In an LCMV 
model, increased Ag load led to greater T cell dysfunction (Wherry et al., 2003), and in 
vitro and in vivo treatment with an activating anti-CD3 mAb to stimulate the CD3 receptor 
resulted in PD-1 upregulation (Agata et al., 1996a). Viral TCD8 epitopes present a strong 
evolutionary pressure, and mutations in these epitopes frequently arise facilitating 
immune escape. When this occurs early in viral infection, the loss of the ability for virus-
specific TCD8 to detect Ag results in lower PD-1 expression (Blattman et al., 2009), and 
TCD8 present in tissues with higher viral loads show increased PD-1 expression 
(Blackburn et al., 2009). PD-1 levels in patients with HIV have also been correlated to 
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viral titers (Trautmann et al., 2006), and TCD8 in patients who are able to control the virus 
without therapy, known as long-term nonprogressors, express relatively low levels of 
PD-1 (Zhang et al., 2007). The expression of high levels of PD-1 on TCD8 is ubiquitous on 
cells displaying an exhausted phenotype, but analysis of functional effector memory cells 
in healthy adults showed that PD-1 was present on these cells as well (Duraiswamy et 
al., 2011).  Further investigation in a system in which the expression of PD-1 was tightly 
genetically controlled demonstrated that levels of PD-1 expression are important. High 
levels of PD-1 were necessary to inhibit macrophage inflammatory protein-1beta (MIP-
1β) production, while moderate levels blocked cytotoxicity and IFNγ production. Very low 
levels of PD-1 could impair TNF, IL-2 production, and proliferation (Wei et al., 2013).   
Less is known about the function of PD-1 during acute viral LRI, but work by 
Erickson et al. highlights that this inhibitory receptor plays an important part in T cell 
exhaustion during pulmonary virus infection (Erickson et al., 2012).  Before this work, 
indirect evidence suggested that TCD8 impairment occurs during RSV infection of mice, 
as IL-2 treatment rescues impairment (Chang et al., 2004), similar to what was seen 
during chronic HIV infection (Blattman et al., 2003). Lung epithelial cells can act as 
APCs and upregulate expression of MHC class I, CD80 and CD86 during infection (Kim 
et al., 2005; Papi et al., 2000), and infection with RSV upregulated expression of PD-L1, 
a ligand for PD-1, on bronchial epithelial cells (Stanciu et al., 2006) leading to the 
inhibition of TCD8 activity (Telcian et al., 2011). These data suggest that the expression of 
the ligand for PD-1 on infected lung epithelium plays a role in the exhaustion phenotype 
seen during viral infection. 
Blockade of PD-1 has recently been pursued as an attractive option for the 
reduction of viral titers in both chronic and acute infections, as well as for improvement 
of TCD8 responses in cancer models.  During chronic LMCV infection, exhausted TCD8 
regained functional capabilities through blockade of the PD-1 pathway leading to 
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enhanced clearance of ongoing infection (Barber et al., 2006). This study demonstrated 
that PD-1 is a major inhibitory pathway in T cell exhaustion and raised the possibility of a 
therapeutic intervention that could improve viral control by targeting T cell exhaustion. In 
vitro blockade of PD-1 on TCD8 generated by HIV infection also showed efficacy in 
restoring function (Day et al., 2006; Freeman et al., 2006; Trautmann et al., 2006), and 
in vivo PD-1 blockade during simian immunodeficiency virus (SIV) infection resulted in 
improved TCD8 responses, greater neutralizing antibody levels and enhanced survival 
(Velu et al., 2009). PD-1 also appears to impair T cells during cancer (Jung et al., 2010), 
and clinical trials indicate that the anti-PD-1 monoclonal antibody, nivolumab, is safe and 
effective against refractory hematological malignancies (Ansell et al., 2015; Berger et al., 
2008) and solid tumors (Brahmer et al., 2010; Herbst et al., 2014; Powles et al., 2014; 
Tumeh et al., 2014). These results show that targeting PD-1 is a viable new 
immunotherapeutic option in the treatment of cancer and chronic infections. Recent work 
from our lab also shows that lung TCD8 rapidly become impaired during acute viral LRI, 
and demonstrates the potential for blockade of PD-1 in the reduction of viral respiratory 
titers (Erickson et al., 2014a). 
PD-1 has two ligands in the B7-family, PD-L1 (B7-H1, CD274)(Freeman et al., 
2000) and PD-L2 (B7-DC, CD273)(Latchman et al., 2001). PD-L1 is thought to be most 
crucial in suppressing autoimmunity (Greenwald et al., 2005) and inducing TCD8 
exhaustion (Barber et al., 2006; Blackburn et al., 2009; Butler et al., 2012; Jin et al., 
2010b) . PD-L1 is constitutively expressed on the surface of T and B cells, DCs, and 
macrophages (Yamazaki et al., 2002), and PD-L1 transcript is expressed by a wide 
range of nonhematopoietic cells (including lung parenchymal cells) (Freeman et al., 
2000). Surface expression of PD-L1 in the latter cell type only occurs after an activating 
signal (Dong et al., 2002). This inhibitory ligand is also expressed on many tumor types, 
and is thought to inhibit tumor-infiltrating TCD8 to promote immune evasion and 
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malignancy (Curiel et al., 2003; Dong et al., 2002; Grosso and Jure-Kunkel, 2013; Iwai et 
al., 2002; Soliman et al., 2014). Innate immune responses play a role in the upregulation 
of PD-L1 as type I IFN signaling as well as double-stranded RNA or lipopolysaccharide 
(LPS) treatment, in a TLR3- and TLR4-dependent manner, respectively, upregulates 
PD-L1 (Eppihimer et al., 2002; Groschel et al., 2008; Schreiner et al., 2004; Terawaki et 
al., 2011). The promoter region of this gene contains two interferon regulatory factor-1 
(IRF-1) sites capable of binding both PRR-mediated IRF3/7 and JAK/STAT-mediated 
ISGF3 (Lee et al., 2006a). IL-27, an innate cytokine associated with a TH17 response, 
has been shown in a model of autoimmune encephalomyelitis to induce the upregulation 
of PD-L1 (Hirahara et al., 2012). Type II IFN signaling can upregulate PD-L1 (Eppihimer 
et al., 2002; Schreiner et al., 2004) by repression of microRNA-513, which prevents PD-
L1 protein from being expressed on the cell surface (Gong et al., 2009). Taken together, 
these results indicate that PD-L1 is upregulated by multiple innate immune mechanisms 
during infection, while control of T cell PD-1 expression is accomplished through the 
specific interaction of the TCR with cognate Ag.  Chapter III of this thesis will investigate 
further the dependence of PD-1:PD-L1 interaction on type I IFN signaling, by using a 
transgenic mouse model lacking the IFN-α receptor (IFNAR). 
 
Other Inhibitory Pathways 
 Exhausted TCD8 also co-express up to seven inhibitory receptors, including TIM-
3, LAG-3, 2B4, and CTLA-4 along with PD-1 (Figure 1-5) (Crawford and Wherry, 2009). 
These inhibitory receptors are capable of working synergistically to affect the severity of 
dysfunction (Blackburn et al., 2009), but PD-1 appears to act as a master regulator of 
exhaustion, and blockade of other receptors, without PD-1 blockade, has minimal impact 
(Barber et al., 2006; Blackburn et al., 2009; Jin et al., 2010b).  However, if PD-1 is 
blocked along with TIM-3 (Jin et al., 2010b), LAG-3 (Blackburn et al., 2009; Butler et al., 
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2012) or CTLA-4 (Kaufmann et al., 2007; Nakamoto et al., 2009) a significant 
enhancement of TCD8 function over PD-1 blockade alone can be observed in chronic 
infections.    
CTLA-4 is closely related (Lin et al., 2008) and antagonizes TCR signaling, 
similar to PD-1, but through a distinct mechanism. During CTLA-4 signaling, this 
molecule binds to CD80/86 (Masteller et al., 2000) activating phosphatases (Chuang et 
al., 2000; Chuang et al., 1999; Cilio et al., 1998; Lee et al., 1998; Marengere et al., 
1996), which blockade lipid-raft expression (Chikuma et al., 2003; Darlington et al., 
2002; Martin et al., 2001; Rudd et al., 2002) and prevent Zap70 microcluster formation 
(Valk et al., 2006). However, PD-1 signaling also induces the transcription factor Basic 
leucine zipper transcription factor, ATF-like (BATF), which further inhibits effector 
functions (Quigley et al., 2010).  Signaling mechanisms for TIM-3, LAG-3 and 2B4 are 
less well understood, and they lack classic motifs associated with T cell signaling (e.g., 
ITIM or ITAM). Expression of inhibitory ligands represents the other side of the TCD8 
exhaustion coin. TIM-3 binds Galectin-9, a secreted molecule; LAG-3 binds MHC class II 
molecules with higher affinity than CD4 (Odorizzi and Wherry, 2012); and 2B4 binds to 
CD48 present on the surface of all hematopoietic cells (Mooney et al., 2004).  The 
availability of different ligands in host niches could fine-tune the functionality of these 
TCD8 to protect sensitive organs, like the lung.  
Inhibitory receptors other than PD-1 are also involved in acute viral LRI, although 
like PD-1, much less is known than in the context of chronic infection.  During Sendai 
virus infection, LAG-3 is capable of negatively regulating TCD8 memory development 
(Workman et al., 2004), TIM-3 limits TCD8 effector functions during acute HSV-1 infection 
(Sehrawat et al., 2010) and influenza infection (Sharma et al., 2011) while LAG3 and 
2B4 inhibits TCD8 function in HMPV and influenza (Erickson et al., 2014a). These data  
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Figure 1-8. TCD8 co-stimulatory molecules. (A) T cell activation is enhanced through the 
interactions with multiple cell-cell interactions that supplement TCR signaling.  CD28 
helps prevent anergy by providing crucial co-stimulation and is required to fully activate 
T cells.  These positive interactions lead to the production of poly-functional effector T 
response.  (B) Inhibitory receptors, like PD-1, TIM-3, LAG-3, 2B4 and CTLA-4, 
antagonize TCR and other positive signals. From (Chen and Flies, 2013).  
 
suggest that synergistic blockade of PD-1 with other inhibitory receptors might be even 
more affective at restoring functionality to impaired TCD8. 
 
Implications of type I IFN evasion on CD8+ T cell response  
The link between the innate and adaptive immune response during viral infection 
has only recently begun to be appreciated, but increasing evidence is mounting that 
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shows that lack of a functional and balanced innate immune response leads to an 
aberrant adaptive immune response (Figure 1-9). As discussed in a previous section, 
viruses have evolved many mechanisms with which to evade type I IFN signaling, but 
not much is known about what this could mean for the adaptive response. There is some 
data on the contribution of IFNAR signaling to the TCD8 response overall, and its 
importance in generating protective immunity. The timing of type I IFN exposure has 
been shown to be very important in controlling the pleiotropic effects of this cytokine, as 
early treatment with type I IFN leads to inhibition of TCD8 responses while treatment 
during or after antigen exposure strongly enhanced immune responses (Gallucci et al., 
1999; Le Bon et al., 2003; Le Bon et al., 2001; Proietti et al., 2002).  
Type I IFN treatment in vitro is capable of directly and potently inhibiting 
proliferation of TCD8 (Figure 1-9)(Lindahl-Magnusson et al., 1972; Petricoin et al., 1997; 
Zella et al., 2000), but this response appears temporally regulated since 3 hours of IFN 
pre-treatment leads to enhanced proliferation, while 18 hours had an opposite effect 
(Feng et al., 2005). Type I IFNs have been shown to act directly on TCD8 to induce 
proliferation in vivo, by a mechanism that overlaps with IL-12 signaling (Curtsinger et al., 
2005; Kolumam et al., 2005b; Thompson et al., 2006), and this signal is particularly 
important for the formation of SLECs (Wiesel et al., 2012). This difference in in vitro 
versus in vivo effects of type I IFN could also be related to changes in migration due to 
chemokine receptor expression and the expression of CD69L (Feng et al., 2005; Shiow 
et al., 2006; Sun et al., 1998). The anti-proliferative properties of type I IFN produces 
differential responses in naïve compared to activated T cells related to the expression 
level of STAT1 in these cell types (Stark et al., 1998), providing a potential mechanism 
for this discordance. Activated T cells express lower levels of STAT1, and this lower 
expression appears to generate resistance to the negative effect of type I IFNs 
(Bromberg et al., 1996; Dondi et al., 2003; Gil et al., 2006; Tanabe et al., 2005). Another 
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mechanism leading to increased survival in vivo of IFN-exposed TCD8 is related to the 
expression level of the natural cytotoxicity triggering receptor 1 (NCR1) ligand, which is 
repressed on the surface of TCD8 by type I IFN signaling. Without expression of this 
molecule, TCD8 are sensitive to perforin-mediated killing by natural killer (NK) cells 
(Crouse et al., 2014). Type I IFNs also directly work on a myriad of other cell types, 
including lung epithelium and APCs, so the overall affect on TCD8 becomes even more 
complex (Hervas-Stubbs et al., 2011; Le Bon et al., 2001; Le Bon et al., 2006; Tough, 
2004). 
APCs are an indispensable component of the TCD8 response, and the different 
subsets have been suggested to differentially prime an effector or memory response 
(Hao et al., 2008; Kim and Braciale, 2009; Kim et al., 2014). Type I IFNs also play a key 
role in the proliferation and maturation of APCs from immature monocytes (Haicheur et 
al., 2000; Paquette et al., 1998; Parlato et al., 2001; Santini et al., 2000). This signaling 
has been shown to be IRF3 mediated, and APCs are able to essentially help themselves 
mature through autocrine IFNAR signaling (Shalek et al., 2013). GM-CSF and IL-4 are 
the most commonly known stimulators of APC development from CD14+ monocytes, but 
type I IFNs can take the place of IL-4 in this phenomenon (Paquette et al., 2002). Type I 
IFNs are also important for the transformation of APCs from an immature to a mature 
developmental stage and can synergize with TNFα and CD40L to enhance maturation 
(Luft et al., 2002; Radvanyi et al., 1999). This developmental shift is associated with the 
upregulation of CD40, CD80, CD86 and MHC class I and II (Ito et al., 2001; Luft et al., 
1998; Padovan et al., 2002; Wang et al., 1999).  
IFN-matured APCs are capable of potently stimulating T cell proliferation both in 
vitro (Mattei et al., 2001; Montoya et al., 2002; Padovan et al., 2002) and in vivo (Le Bon 
et al., 2001). These cells also secrete chemokines that are important for the trafficking of 
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TCD8 to sites of infection and cytokines that can regulate immune responses. APCs 
matured in the presence of type I IFN upregulate the expression of CXCL9 (MIG), 
Figure 1-9. Direct affect of type I IFN on T cells promotes overall TCD8 response. Type I 
IFN is responsible for pleiotropic affects on the T cell response. It induces the apoptosis 
of memory T cells, promoting a broad CTL response, and stimulates the proliferation and 
survival of activated T cells, permitting a vigorous CTL response. Type I IFN also 
restricts the maintenance of Treg cells, which suppress T cell effector functions allowing 
for a functional CTL response. 
 
CXCL11 (I-TAC), CXCL10 (IP-10), CXCL19 (MIP-3β), and/or DC-CK-1 depending on 
secondary maturation signals. These chemokines bind to activated T cells, except for 
CXCL19 and DC-CK-1 that act on naïve T cells (Adema et al., 1997; Ngo et al., 1998), 
and allow for the efficient migration of TCD8 to sites of infection (Padovan et al., 2002; 
Parlato et al., 2001). The secretion of IL-15 by IFN-matured APCs provides a stimulatory  
signal to maturing T cells as well as to the secreting cell promoting an activating loop for 
this interaction (Mattei et al., 2001; Santini et al., 2000). 
Type I IFN also contributes to the polarization of the CD4+ T cell response 
towards a Th1-biased response, and away from a Th2 or Th17 response (Eriksen et al., 
2004; Huber et al., 2010; Moschen et al., 2008; Schandene et al., 1996; Shibuya and 
Hirohata, 2005), which generates a favorable environment for TCD8 effector functions. 
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Finally, regulatory CD4+ T cells (Treg) suppress effector TCD8 functions and proliferation 
(Almeida et al., 2010), and a recent LCMV study shows that type I IFN signaling in Treg 
cells suppresses CD28-dependent ICOS expression, ultimately leading to suppression 
of proliferation of these cells (Figure 1-9)(Srivastava et al., 2014b). My work contributes 
new information to this question. Contrary to the Srivastava et al. study, my data 
presented in chapter IV of this thesis I showed that during HMPV infection of IFNAR KO 
mice lower levels of CD25+ FOXP3+ CD4+ T regulatory can be found in the lungs, 
perhaps indicating a trafficking defect related to chemokine expression.  
Taken together, these data show that type I IFN is important for a potent TCD8 
response, and that the RSV interferon antagonist NS1 is capable of skewing the T cell 
response in vitro. In that study, virus without interferon antagonist ability demonstrated 
three clear differences from WT virus. First, without NS1, TCD8 upregulated CD103, 
shown earlier to be important for tissue homing during infection.  Second, activation and 
proliferation of Th17 cells was increased, and third, IL-4 producing CD4+ T cells, a major 
contributor to disease pathogenesis, were reduced (Munir et al., 2011). This is strong 
evidence that innate immune evasion, well described for many viruses, can play a role in 
modulation of the adaptive response. Work in this thesis will use HMPV to explore the 
contributions of type I IFN signaling to viral control and pathogenesis, functional and 
robust TCD8 response and the newly described phenomenon of TCD8 impairment during 
acute viral LRI. 
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CHAPTER II 
 
HMPV evades type I IFN signaling through targeting STAT1 with the small 
hydrophobic (SH) protein 
Introduction 
Human metapneumovirus (HMPV) is a negative sense, single-stranded RNA 
virus in the Paramyxoviridae family (van den Hoogen et al., 2001b). Infection with HMPV 
is a leading cause of acute lower respiratory infections (LRI), and no treatment or 
vaccine is currently available to combat this pathogen (Edwards et al., 2013; Englund et 
al., 2006b; Papenburg et al., 2012; Shahda et al., 2011; Walsh et al., 2008; Widmer et 
al., 2012; Williams et al., 2004; Williams et al., 2005b; Williams et al., 2006b). By the age 
of five, nearly all individuals will have been infected with HMPV (van den Hoogen et al., 
2001b) and contain neutralizing antibodies toward this virus, but the very young, the 
elderly, and immunocompromised will be at high risk of developing severe complications 
from this viral infection (14, 17, 36).  HMPV, like other members of the Paramyxoviridae 
family such as respiratory syncytial virus (RSV) and parainfluenza virus (PIV), is capable 
of blocking or modulating the innate immune response through targeting of molecules 
involved in signaling through the type I interferon (IFN) signaling pathway (Dinwiddie and 
Harrod, 2008; Ren et al., 2011).  Type I IFN signaling begins with the recognition of viral 
nucleic acids by pattern recognition receptors (PRRs) in infected cells (Platanias, 2005), 
as well as in innate immune cells such as macrophages and dendritic cells (Gordon, 
2002), which induce the production and release of type I IFNs, IFNα and IFNβ. These 
molecules ligate the interferon α receptor (IFNAR), in both an autocrine and paracrine 
fashion, and lead to signaling events, involving STAT1, STAT2, and IRF9, which 
culminate in the expression of anti-viral effector molecules (Barber, 2001; Biron, 2001; 
Sadler and Williams, 2008). In addition, this pathway is capable of modulating the 
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adaptive immune response by contributing to both the presentation of antigens as well 
as the differentiation and maintenance of important adaptive immune cells (Havenar-
Daughton et al., 2006; Kolumam et al., 2005a; Le Bon and Tough, 2008; Luft et al., 
1998).  
Related paramyxoviruses, such as RSV and PIV, encode proteins responsible for 
targeting and inhibiting signaling through the innate immune pathways.  RSV encodes 
the NS1 and NS2 proteins, and the PIV genome contains an alternative reading frame of 
the P/C/V gene that encodes the V protein; both types of proteins specifically inhibit 
aspects of innate immunity (Andrejeva et al., 2004; Childs et al., 2012; Gainey et al., 
2008; Lo et al., 2005).  Interestingly, the HMPV genome contains no analogous open 
reading frames to any of these previously identified innate immune antagonists 
(Piyaratna et al., 2011; van den Hoogen et al., 2002). Specifically, many related viruses 
have mechanisms to affect STAT1 expression and phosphorylation (Didcock et al., 
1999a, b; Kubota et al., 2001; Ramaswamy et al., 2004; Takeuchi et al., 2003), 
(Rodriguez et al., 2004; Rodriguez et al., 2002), and data in the field indicates that 
HMPV is no different (Dinwiddie and Harrod, 2008; Ren et al., 2011). This led us to 
hypothesize that HMPV is using a viral protein in a unique way to evade the type I IFN 
signaling pathway by targeting STAT1.  In this study, we sought to determine the viral 
protein responsible for inhibition of STAT1 phosphorylation. 
 
Results  
 
HMPV infection increases STAT1 expression and inhibits type I IFN induced 
STAT1 phosphorylation in BEAS-2B cells 
To characterize the effect of HMPV infection on STAT1 expression and 
phosphorylation, we first used the human bronchial epithelial cell line, BEAS-2B. After 24 
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hours of HMPV infection, cells were treated with type I IFN for 15 minutes and STAT1 
expression and phosphorylation levels were determined using western blotting analysis 
(Figure 2-1A). Image J software was used to quantify band intensity for this western blot 
(Figures 2-1B and C). STAT1 expression did not change in cells infected with HMPV 
(Figure 2-1A and B). However, in infected BEAS-2B cells treated with type I IFN, STAT1 
phosphorylation was markedly lower than in IFN-treated uninfected cells (Figure 2-1A 
and 1C). We next used flow cytometry to measure both expression and IFN-induced 
phosphorylation of STAT1 in bulk populations of BEAS-2B cells infected with HMPV. 
Using this assay we observed an increase in total STAT1 expression in BEAS-2B cells 
over the course of 48 hours of HMPV infection (Figure 2-1D), as well as a significant 
decrease in the ability of the infected BEAS-2B cells to phosphorylate STAT1 upon type 
I IFN treatment (Figure 2-1E). This suggests that HMPV is capable of inhibiting STAT1 
phosphorylation in these cells.  
 
Type I IFNs produced by infected BEAS-2B cells induce high STAT1 levels, and 
cells become refractory to STAT1 phosphorylation  
In order to analyze the ability for HMPV to inhibit STAT1 phosphorylation 
specifically in infected cells, we used fluorescent antibody staining to selectively label 
cells that were infected with HMPV and expressing viral proteins (Figure 2-2A). Flow 
cytometry was then used to analyze STAT1 expression and IFN-induced 
phosphorylation in HMPV-infected and uninfected cells. STAT1 expression significantly 
increased in both infected and uninfected BEAS-2B cells in the same well compared to 
cells treated with lysate from uninfected LLC-MKC cells used to grow HMPV (mock) 
treated cells, but expression in infected cells was lower than the uninfected cells in the 
same well (Figure 2-2B). When cells infected with virus were treated with type I IFN at 
time-points during the course of infection, we observed that over 24 hours of HMPV  
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Figure 2-1: Affect of HMPV on BEAS-2B cells. (A) BEAS-2B Cells were infected for 48 
hours with HMPV at MOI of 4. Cells were lysed with RIPA buffer, and proteins were 
separated on 4-15% bis-tris Gel before transfer to nitrocellulose membrane. The 
membrane was probed with antibodies against STAT1, the phosphorylated isoform of 
STAT1, and tubulin.  (B,C) Quantification of western blot. (D,E)   BEAS-2B cells infected 
for 48 hours with HMPV at MOI of 4. Cells were fixed and permeabilized and fluorescent 
antibodies and used to probe for STAT1 and the phosphorylated isoform of STAT1 using 
flow cytometry. Groups were compared using an unpaired Student’s t test or one-way 
ANOVA with Tukey post-hoc test where appropriate. N > 3. Error bars represent SEM. 
****=P<0.0001. 
 
A
C
B
Figure 1:
(A) BEAS2B Cells infected for 24 hours with HMPV at MOI of 
1. Cells lysed with RIPA buffer, and ran on 4-15% bis-tris Gel 
before transfer to nitrocellulose membrane. Probed with 
antibodies towared STAT1, the phosphorylated isoform of 
STAT1, and tubulin.  (B,C) Quantification of western blot. (D,E)   
BEAS2B cells infected for 48 hours with HMPV at MOI of 4. 
Cells were fixed and permeabilized and fluorescent antibodies 
were used to probe for STAT1 and the phosphorylated isoform 
of STAT1 using flow cytometry. Groups were compared using 
unpaired t test or one-way ANOVA with post-hoc Tukey test 
where appropriate. N > 3. Error bars represent SEM. 
****=P<0.0001.
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infection, both infected cells and uninfected cells in the same well displayed a loss of the 
ability to phosphorylate STAT1 in response to treatment with type I IFN (Figure 2-2C).  
Since uninfected cells cultured with HMPV-infected cells also lost the ability to 
phosphorylate STAT1, we tested the hypothesis that this inhibition of STAT1 
phosphorylation was driven by host factors instead of a direct viral effect. We tested 
whether prolonged exposure to type I IFN alone could induce this phenotype. We found 
that after a 24-hour treatment of BEAS-2B cells with exogenous or endogenous type I 
IFN (the latter induced by poly(I:C) transfection) that these cells significantly upregulated 
STAT1 expression (Figure 2-2D) and lost the ability to phosphorylate STAT1 when 
treated with type I IFN (Figure 2-2E). These findings led us to conclude that type I IFN 
produced by HMPV-infected cells was inducing a non-responsive state in surrounding 
uninfected cells in the well, thus hampering the ability to detect a specific viral effect 
within the infected cell population. Vero cells are defective in the production of type I 
IFNs (Emeny and Morgan, 1979a, b) and provided a tractable alternative. We found no 
effect of transfection of poly(I:C) on either STAT1 expression (Figure 2-2D) or STAT1 
phosphorylation (Figure 2-2E) in the Vero cell line. These data show that the inability of 
BEAS-2B cells to phosphorylate STAT1 after HMPV infection is partly driven by 
paracrine type I IFN production during infection, and that use of the Vero cell line can 
avoid this confounding effect. 
 
HMPV infection of Vero cells leads to lower STAT1 expression and a significant 
defect in the ability to phosphorylate STAT1 specifically in infected cells   
To determine the effect of HMPV infection on STAT1, Vero cells were infected at 
an MOI of 1, treated with type I IFN 24 hours later, than analyzed for STAT1 expression 
and phosphorylation by western blot (Figure 2-3A). No difference was detected in total 
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Figure 2-2.: Effect of type I IFN treatment on BEAS-2B cells. (A) Cells infected with 
HMPV were identified with antibody to HMPV antigen and gated into distinct populations 
of infected and uninfected cells using flow cytometry. (B) Cells were also probed with 
fluorescently labeled antibodies against STAT1 (B,D) or phosphorylated STAT1 (C,E), 
and analyzed via flow cytometry after treatment with HMPV (B,C), type 1 IFNs, or 
synthetic viral RNA, Poly(I:C), to induce IFN expression (D,E). Groups were compared 
using unpaired Student’s t test or one-way ANOVA with Tukey post-hoc test where 
appropriate. N = 2-3 duplicate experiments. Error bars represent SEM. *=P<0.05, 
****=P<0.0001. 
A
Figure 2:
(A) Cells infected with HMPV are identified with 
antibody to HMPV antigen and gated into distinct 
populations of infected and uninfected cells using flow 
cytometry. (B) Cells were also probed with fluorescently 
labeled STAT1 expression (B,D) or phosphorylation 
(C,E) antibody, and analyzed via flow cytometry after 
treatment with HMPV (B,C), type 1 IFNs, or synthetic 
viral RNA, Poly(I:C), treatment to induce IFN expres-
sion (D,E) to determine affects of treatment on STAT1. 
Groups were compared using unpaired t test or one-way 
ANOVA with post-hoc Tukey test where appropriate. N = 
2-3 duplicate experiments. Error bars represent SEM. 
*=P<0.05, ****=P<0.0001.
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STAT1 expression between infected and mock-treated bulk cell populations (Figure 3A, 
B), but interestingly lower molecular weight isoforms of STAT1 appear in these cells 
when they were infected with HMPV (Figure 2-3A). IFNα-driven STAT1 phosphorylation 
seemed to also slightly decrease STAT1 phosphorylation (Figure 2-3A and C). As 
observed before, it is important to look specifically at infected cells to determine a viral 
affect on STAT1. Flow cytometric analysis of Vero cells infected with an MOI of 1 was 
performed using an anti-HMPV antibody to differentiate between uninfected and infected 
cells as in Figure 2-2. We found lower STAT1 expression in HMPV-infected cells 
compared to uninfected cells in the same well (Figure 2-3D). When these cells were 
treated with IFNα, there was significant defect in the ability of infected cells to 
phosphorylate STAT1 (Figure 2-3E). These results show that HMPV is capable of 
decreasing STAT1 expression and inhibiting IFN-induced STAT1 phosphorylation in 
Vero cells. 
 
Vero cells transiently expressing the SH protein from HMPV display lower STAT1 
expression and phosphorylation induced by both type I and II IFN   
To identify which HMPV protein was responsible for the inhibition of IFN-induced 
STAT1 phosphorylation, we generated GFP-tagged viral protein expression plasmids 
optimized for mammalian cell expression. We used flow cytometry to analyze Vero cells 
expressing viral proteins compared to non-transfected cells in the same well by gating 
on GFP (Figure 2-4A). In cells expressing the HMPV SH protein, there was significantly 
lower STAT1 expression compared to untransfected cells in the same well after 48 
hours, but no difference in STAT1 expression was observed upon transfection of other 
viral proteins or GFP alone (Figure 2-4B). When these cells were treated with IFNα, the 
cells expressing SH were significantly inhibited in their ability to phosphorylate STAT1 
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Figure 2-3. Specific viral inhibition of STAT1 by HMPV in Vero cells. (A) Vero Cells 
infected for 48 hours with HMPV at MOI of 4. Cells were lysed with RIPA buffer, and 
proteins were separated on 4-15% bis-tris Gel before transfer to nitrocellulose 
membrane. The membrane was probed with antibodies toward STAT1, the 
phosphorylated isoform of STAT1, and tubulin.  (B,C) Quantification of western blot. 
(D,E)   Vero cells were infected for 48 hours with HMPV at MOI of 1. Cells were fixed 
and permeabilized and fluorescent antibodies were used to probe for STAT1 and the 
phosphorylated isoform of STAT1 specifically in cells expressing viral antigen using flow 
cytometry.  Groups were compared using an unpaired Student’s t test or one-way 
ANOVA with post-hoc Tukey test where appropriate. N > 3 duplicate experiments. Error 
bars represent SEM. *=P<0.05. 
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Figure 3:
(A) Vero Cells infected for 24 hours with HMPV at MOI of 1. 
Cells lysed with RIPA buffer, and ran on 4-15% bis-tris Gel 
before transfer to nitrocellulose membrane. Probed with 
antibodies towared STAT1, the phosphorylated isoform of 
STAT1, and tubulin.  (B,C) Quantification of western blot. (D,E)   
Vero cells infected for 48 hours with HMPV at MOI of 1. Cells 
were fixed and permeabilized and fluorescent antibodies were 
used to probe for STAT1 and the phosphorylated isoform of 
STAT1 specifically in cells expressing viral antigen using flow 
cytometry.  Groups were compared using unpaired t test or 
one-way ANOVA with post-hoc Tukey test where appropriate. N 
> 3 duplicate experiments. Error bars represent SEM. *=P<0.05.
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(Figure 2-4C).  Similar inhibition was observed when treated with IFNγ (Figure 2-4D). 
Cells expressing the N protein from HMPV also showed a modest but significant defect 
in type II IFN-induced STAT1 phosphorylation (Figure 2-4D). Thus, the HMPV SH 
protein is capable of preventing IFN-induced phosphorylation of STAT1. 
 
Figure 2-4. Effect of transient HMPV protein expression on STAT1. (A) Vero cells 
transfected with HMPV GFP-fusion proteins were specifically analyzed using flow 
cytometry compared to the untransfected cells in the same culture. STAT1 expression 
(B) and phosphorylation (C,D) was analyzed using fluorescently labeled antibodies in the 
context of treatment with IFNα (C) and IFNγ (D). Groups were compared using unpaired 
Student’s t test or one-way ANOVA with Tukey post-hoc test where appropriate. N =/>3 
duplicate experiments per group. Error bars represent SEM. *=P<0.05, **=P<0.01, 
***=P<0.001. 
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Stable expression of the HMPV SH protein increases STAT1 expression, but 
reduces IFN-induced STAT1 phosphorylation and downstream type I IFN signaling 
As a complementary approach to transient transfection, cell lines were generated 
that stably expressed HMPV proteins. There was a significant increase in baseline 
STAT1 expression in cells constitutively expressing SH protein compared to the parental 
cells (Figure 2-5A). There was also a modest but significant increase in the level of 
STAT1 protein in cells expressing HMPV G and P. When treated with IFNα, cells 
expressing SH protein showed significantly lower levels of STAT1 phosphorylation 
compared to the parental cells (Figure 2-5B), similar to the defect observed during 
transient transfection of viral proteins. To confirm that inhibition of STAT1 
phosphorylation led to a reduction of downstream signaling through the type I IFN 
pathway, we utilized a luciferase reporter plasmid containing the promoter region of the 
interferon stimulated response element (ISRE). Cells stably expressing either the N or 
SH proteins exhibited a significant defect in the ability to signal through the type I IFN 
pathway (Figure 2-5C). These data show that the stable expression of the SH protein is 
capable of inhibiting phosphorylation of STAT1 by type I IFN and that this inhibition 
decreases signaling through the type I IFN pathway. 
 
Discussion 
HMPV is an important human pathogen and is capable of causing significant morbidity 
and mortality, particularly in vulnerable populations including the very young, elderly and 
immunocompromised persons (Edwards et al., 2013; Englund et al., 2006b; Papenburg 
et al., 2012; Shahda et al., 2011; Walsh et al., 2008; Widmer et al., 2012; Williams et al., 
2004; Williams et al., 2005b; Williams et al., 2006b) . Similar clinical disease is caused 
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Figure 2-5. Effect of stable expression of HMPV on STAT1 and downstream ISRE 
signaling. The effect of stable expression of HMPV proteins on STAT1 in 293FLP cells 
was measured using fluorescently conjugated antibodies for STAT1 expression (A) and 
phosphorylation (B) induced by type 1 IFN treatment via flow cytometry. Stably 
transfected cell lines were also used to measure downstream activation of the type 1 IFN 
pathway by the transfection of an ISRE-luciferase reporter and the subsequent treatment 
of cells with type 1 IFN (C).  N =/>3 duplicate experiments per group. Groups were 
compared using an unpaired Student’s t test or one-way ANOVA with Tukey post-hoc 
test where appropriate. N = 3 duplicate experiments. Error bars represent SEM. 
*=P<0.05. 
 
 
by HMPV to that seen in other related virus infections, like RSV and PIV (Fox, 2007; 
Freymuth et al., 1995; Freymuth et al., 2006; Garcia-Garcia et al., 2006), despite the 
absence of sequence homology in the HMPV genome for previously known innate 
immune agonists (Piyaratna et al., 2011; van den Hoogen et al., 2002). Both type I and II 
IFN signaling rely on STAT1 as a crucial component in both pathways. After ligation of 
A
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B
Figure 5:
The effect of stable expression of HMPV proteins on STAT1 
in 293FLP cells was measured using fluorescently conju-
gated antibodies for STAT1 expression (A) and phosphoryla-
tion (B) induced by type 1 IFN treatment via flow cytometry. 
Stably transfected cell lines were also used to measure 
downstream activation of the type 1 IFN pathway by the 
transfection of an ISRE-luciferase reporter and the subse-
quent treatment of cells with type 1 IFN (C).  N =/>3 
duplicate experiments per group. Groups were compared using 
unpaired t test or one-way ANOVA with post-hoc Tukey test 
where appropriate. N = 3 duplicate experiments. Error bars 
represent SEM. *=P<0.05,
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IFNα or β to the type I IFN receptor, Janus kinases (Tyk2/JAK1) associated with the 
receptor cytoplasmic tail phosphorylate STAT1 (Tyr701) and STAT2 (Tyr689), which 
together with IRF9 form a transcription factor, interferon stimulated gene factor 3 
(ISGF3) capable of binding to promoter elements for genes associated with the anti-viral 
response (Platanias, 2005). For type II IFN signaling, IFNγ binds to the IFNGR inducing 
phosphorylation of STAT1 (Tyr701) by other Janus kinases (JAK1/JAK2) resulting in a 
homodimer of STAT1 that acts as a transcription factor for anti-viral proteins, cytokines, 
and chemokines (Platanias, 2005). Type I and II IFN signaling induce an overlapping set 
of anti-viral molecules and act in combination to produce a cellular anti-viral response 
(Decker et al., 2005; Pestka et al., 2004; Schroder et al., 2004). 
In our initial studies, we used the clinically relevant bronchial epithelial cell line, 
BEAS-2B, to determine the effect of HMPV infection on IFN signaling. Experiments 
using total cell populations showed that during viral infection, cells upregulated STAT1 
expression and showed lower IFN-induced phosphorylation of STAT1. However, by 
using flow cytometry to discriminate uninfected and infected cells, we found that infection 
of BEAS-2B cells induced a significant increase in STAT1 expression in both infected 
and uninfected cells in the same well, along with greatly reducing the ability for IFNα to 
induce STAT1 phosphorylation in both populations. The effect on uninfected cells in the 
same well as HMPV-infected BEAS-2B cells led us to speculate that type I IFNs 
secreted by infected cells were working in a paracrine fashion on uninfected cells, thus 
confounding the HMPV-specific STAT1 inhibition in infected cells with type I IFN-induced 
STAT1 downregulation in nearby uninfected cells (Isaacs and Lindenmann, 1957). 
Treatment of BEAS-2B cells with exogenous IFNα or poly(I:C) confirmed that type I IFN 
induced a natural downregulation of  STAT1 expression and phosphorylation. This 
phenomenon presented a challenge for analyzing virus-specific effects on STAT1 within 
the subset of infected cells within an entire cell population. Notably, many studies of 
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related viruses use cell lines competent for type I IFN production, suggesting that 
paracrine effects of type I IFN may confound similar experiments (Ren et al.). 
Vero cells are defective for the production of type I IFN, but are capable of 
responding to exogenous type I IFN (Emeny and Morgan, 1979a; Hasler and Wigand, 
1978). We confirmed that, unlike BEAS-2B cells, poly(I:C) treatment of these cells 
neither increased STAT1 expression nor inhibited IFN-induced STAT1 phosphorylation. 
Analysis of Vero cells via western blotting analysis showed that HMPV infection had no 
effect on STAT1 expression, but induced a striking inability to phosphorylate STAT1 in 
response to type I IFNs. Further investigation using flow cytometry to discriminate 
uninfected from infected cells revealed that HMPV-infected cells displayed significantly 
lower levels of STAT1 expression and IFN-induced phosphorylation of STAT1 compared 
to uninfected cells from the same well. 
The phenomenon of targeting STAT proteins is a mechanism by which other 
viruses from the Paramyxoviridae family evade innate immune signaling through a 
variety of inhibitory actions (Caignard et al., 2007; Takeuchi et al., 2003). The V protein 
from PIV5 and mumps virus in the Rubulavirus genus, and the NS1 protein from RSV, in 
the Pneumovirinae subfamily with HMPV, have been shown to target the STAT proteins 
for proteosomal degradation (Didcock et al., 1999a, b; Kubota et al., 2001; Ramaswamy 
et al., 2004). The measles virus, by contrast, does not affect STAT protein expression, 
but uses the V protein to prevent STAT phosphorylation and thereby blocking the 
association and nuclear translocation of the ISGF3 transcription factor (Takeuchi et al., 
2003). The Nipah virus V protein is capable of binding to STAT proteins and inducing the 
conglomeration of high-molecular-weight complexes, which blocks type I IFN signaling 
(Rodriguez et al., 2004; Rodriguez et al., 2002).  
The HMPV genome contains eight gene segments encoding nine known proteins 
(van den Hoogen et al., 2002). Some of these proteins have well-defined roles in the 
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viral life cycle, such as the RNA polymerase (L), the matrix (M) protein which coats the 
inner layer of the viral membrane, and the fusion (F) protein responsible for binding and 
fusion of the viral particle to the host cell (Piyaratna et al., 2011; van den Hoogen et al., 
2002). Others such as the M2-1, M2-2, and small hydrophobic (SH) proteins play a more 
enigmatic role. Other groups have shown possible roles for the phosphoprotein (P), M2-
2, the glycoprotein (G), and the SH protein in the evasion of innate immune responses to 
HMPV. One study reported a differential ability for the A and B subgroups of HMPV to 
induce type I IFN, and suggested that the P protein of the B1 subgroup of HMPV was 
able to prevent RIG-I activation and the production of IFNs (Goutagny et al.). It is unclear 
whether this inhibition is a result of direct interactions with host innate immune sensors, 
if it is a result of the P protein’s interactions with viral RNA, or if it is an affect on the 
translation of other viral proteins. The M2-2 protein is not necessary for viral growth, but 
published data suggest that it might target the important PRR mediator, mitochondrial 
antiviral-signaling protein (MAVS), to prevent innate immune signaling and thus block 
type I IFN production (Ren et al.). The G protein of HMPV has been suggested to play a 
role in the direct inhibition of RIG-I through interactions between the CARD domain of its 
N-terminus (Ren et al.), leading to higher levels of inflammatory cytokine production in 
cells infected with HMPV lacking the G protein.    
Transient expression of the SH-GFP protein reduced the level of STAT1 
expression and showed a block in IFNγ-induced STAT1 phosphorylation. Surprisingly, 
cells stably expressing the SH protein expressed significantly more STAT1 compared to 
the parental cell line, though SH-expressing cells demonstrated a defect in IFN-induced 
STAT1 phosphorylation and signaling through the ISRE. Since expression of 
unphosphorylated STAT proteins is important for the constitutive expression of important 
host molecules (Chatterjee-Kishore et al., 2000) and because signaling through the type 
I IFN system relies on the accessibility of STAT1 in the cytoplasm (Ramana et al., 2000), 
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it is possible that these cells are compensating for the SH protein targeting of STAT1. 
Collectively, these data indicate that the HMPV SH protein is capable of inhibiting IFNAR 
signaling by targeting the STAT1 protein. 
The function of the SH protein of HMPV has not been fully characterized. The SH 
protein is predicted to be to be a type II transmembrane protein and is present across 
the Pneumovirinae subfamily, but HMPV encodes the longest SH protein at around 180 
aa (van den Hoogen et al., 2002). Sequence homology between HMPV SH and related 
viruses is very low (Biacchesi et al., 2004a; Yunus et al., 2003) but maintains key 
characteristics such as similar hydrophilicity and a high percentage of threonine and 
serine residues (Piyaratna et al., 2011). Recent data indicate that, similar to the RSV SH 
protein, the HMPV SH protein is capable of forming pores in the membrane of infected 
cells, termed a “viroporin”, which increases cell permeability (Masante et al., 2014). This 
is particularly intriguing in the context of our work, because dephosphorylated STAT1 
has been shown to interact with the host nucleoporins, Nup153 and Nup214, in order to 
translocate out of the nucleus after signaling (Marg et al., 2004). The SH proteins of 
PIV5 and RSV are also capable of inhibiting TNF-α signaling in vitro (Fuentes et al., 
2007; Lin et al., 2003; Wilson et al., 2006), and a similar role for SH-HMPV has been 
proposed (Ren et al.) indicating a immunomodulatory role for this protein might not be 
unexpected. 
Recombinant HMPV lacking the SH protein showed no difference in viral kinetics or 
pathogenesis in a small rodent model of HMPV (Biacchesi et al., 2004b) and gene 
expression analysis of A549 cells infected with the SH-deficient virus showed few 
differences from cells infected with WT virus (de Graaf et al., 2013). Despite these data, 
there are significant limitations in extrapolating animal and cell culture data to human 
disease, and as our BEAS-2B experiments showed, analysis of gene or protein 
expression in bulk cell populations may be confounded by paracrine artifacts.  Together, 
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these data show that HMPV SH protein is capable of inhibiting interferon signaling by 
blocking STAT1 expression and IFN-induced phosphorylation. Further studies are need 
to elucidate the role of this inhibition in pathogenesis. 
 
Materials and Methods 
 
 
Cells and Virus. BEAS-2B (ATCC® CRL-9609™) cells were purchased from ATCC. 
FLP-In 293 cells were purchased from Life Technologies. Vero (ATCC® CCL-81™) cells 
were kindly provided by Dr. James Crowe. BEAS-2B cells were maintained in Opti-Mem 
with 2% FBS. Vero cells and 293FLP cells were maintained in DMEM with 10% FBS. 
HMPV (pathogenic clinical strain TN/94-49, genotype A2) was grown and titered in LLC-
MK2 cells as previously described (Williams et al., 2005c). For type I IFN treatment to 
observe STAT1 phosphorylation, cells were incubated with 1000U/mL recombinant 
human interferon alpha A (Alpha 2a)(PBL) for 15 minutes. For long-term type I IFN 
treatment, cells were incubated with 1000U/mL interferon alpha for 24 hours. Poly(I:C) 
treatment was achieved by transfecting 5µg/well Polyinosinic-Polycytidylic acid sodium 
salt (Sigma) into a 24-well plate using Lipofectamine 2000 (Life Technologies) and 
incubating cells for 24 hours. Cell lines stably expressing viral proteins were generated 
using the FLP-In system (Life Technologies) according to the manufacturer’s 
instructions, and selected using hygromycin. 
 
Plasmids. Mammalian optimized viral protein constructs were designed using the 
GeneOptimizer® software (GeneArt) by adjusting codon usage and optimizing GC 
content to be efficiently expressed in mammalian cells. Viral protein sequences were 
then cloned into a pcDNA3.1 plasmid, and into the pcDNA3.1-GFP plasmid to create 
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viral protein-GFP fusion constructs. Transfection was performed using Lipofectamine 
2000 (Life Technologies) according to the manufacturer’s instructions.   
 
Flow Cytometry. Stable cell lines were detached using 0.1% Trypsin-EDTA, washed, 
fixed with 3% buffered formalin for 10 minutes at room temperature, and permeabilized 
with 100% methanol for 10 minutes at -20 ºC. After fixation and permeabilizing, cells 
were washed thoroughly with PBS with 2% FBS. For labeling of HMPV-infected cells, 
samples were incubated with polyclonal guinea pig anti-HMPV sera and FITC-labeled 
anti-guinea pig IgG (Southern Biotech). Cells were also probed with a PE-labeled 
antibody to STAT1 (clone 1/STAT1, BD Phosflow) to determine overall expression 
levels, and with an AlexaFluor-647 labeled antibody to assess phosphorylation of STAT1 
(pY701) (clone 4a, BD Phosflow) after treatment with type I IFN.   
 
Reporter Gene Assay. A firefly luciferase reporter plasmid with 6x copies of the ISRE 
promoter (Stratagene) and a constitutively active Renilla luciferase reporter on a TK 
promoter (pGL4.74, Promega) were co-transfected into cell lines stably expressing 
HMPV genes to measure the binding activity of the ISRE transcription factor. Twenty-
four hours post-infection, cells were treated with type I IFN for 24 hours, and the Dual-
Glo luciferase assay system (Promega) was used to measure the signal for each 
luciferase type. The constitutively active Renilla luciferase signal was used to normalize 
transfection efficiency across the experiment. 
 
Western Blot. Cells were mock- or HMPV-infected at ~80% confluency and infection 
was allowed to progress for 48 hours before IFN-α treatment for 30 minutes. Cells were 
washed on ice with 1x PBS and then lysed using ice-cold RIPA buffer (10 mM Tris, pH 
7.4, 150 mM NaCl, 1% Triton X-100, 1% deoxycholate, 0.1% SDS, and 5 mM EDTA) 
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supplemented with protease (P8340, Sigma) and phosphatase inhibitors (Roche).  
Protein concentration was determined using a DCTM protein Assay (BioRad), and 
samples were diluted in a 5x sample buffer (250mM Tris HCl (pH 6.8), 10% SDS, 0.5% 
bromophenol blue, 50% glycerol, and 100mM DTT). Clarified lysates were boiled for ten 
minutes, subjected to SDS/PAGE, and transferred onto nitrocellulose membranes.  
Membranes were blocked for 1 hour in 5% nonfat dry milk in tris-buffered saline with 
0.1% Tween-20 V/V (TBS-T) buffer followed by incubation in p-STAT1 (Clone A-2, Santa 
Cruz, sc-8394), STAT1 (Clone H-95, Santa Cruz, sc-96783), or β-tubulin (mouse 
monoclonal, Sigma, #T4026) primary antibodies.  Blots were washed in TBS-T and 
subsequently incubated with HRP-conjugated secondary antibodies (Promega).  Signal 
was detected using the Clarity Western ECL substrate (Bio-Rad). Quantification of 
western blot analysis in figure 1B and C and figure 3B and C was performed using the 
Image J software to calculate band intensity. For STAT1 phosphorylation, intensity of 
phosphorylated band was calculated relative to STAT1 expression for each sample.   
 
Statistical Analyses. Data analysis was performed using Prism v4.0 (GraphPad 
Software). Groups were compared using an unpaired Student’s t-test or one-way 
ANOVA with Tukey post-hoc test for multiple comparisons. P <0.05 was considered to 
be significant.  
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CHAPTER III 
 
Type I IFN signaling controls early viral replication, but also contributes 
significantly to disease pathogenesis 
Work presented in this chapter also published in the Journal of Virology (Hastings et al., 2015) 
 
Introduction 
HMPV, like other members of the Paramyxoviridae family such as respiratory 
syncytial virus (RSV) and parainfluenza viruses (PIV), can subvert the innate immune 
response through modulation of the type I interferon (IFN) signaling pathway (Dinwiddie 
and Harrod, 2008; Ren et al., 2011).  Type I IFN signaling, which is initiated through 
activation of the interferon α receptor (IFNAR), is thought to be integral to the early 
immune response through the induction of anti-viral effector molecules (Barber, 2001; 
Biron, 2001; Sadler and Williams, 2008). Recent data has also revealed a role for type I 
IFN signaling in the pathogenesis of respiratory diseases. An IFNAR-deficient model of 
RSV infection shows significantly greater inflammatory cytokine levels and weight loss 
than infected WT mice (Goritzka et al., 2014).  
 Type I IFNs have been shown to initiate cyclic signaling cascades responsible for 
the production of an inflammatory response. In studies of Francisella, researchers have 
shown that type I IFN is capable of upregulating the absent in melanoma 2 (AIM2) 
inflammasome (Choubey et al., 2010; Fernandes-Alnemri et al., 2010). AIM2 activation 
results in caspase1 activation and the production of IL-1β and IL-18, as well as 
pyroptosis in infected cells (Fernandes-Alnemri et al., 2009). Type I IFN are also able to 
induce apoptosis, in conjuction with TLR3 and TLR4, through the suppression of Akt 
signaling and degradation of the CDK inhibitory protein, p27. RIG-I, and MDA5, shown to 
be important in innate signaling of HMPV (Banos-Lara Mdel et al., 2013; Goutagny et 
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al.), are also upregulated by type I IFN signaling (Haller et al., 2006; Jaitin and 
Schreiber, 2007). These receptors signal through the mitochondrial adaptor IPS-1 to 
induce the production of proapoptotic BCL-2 homology 3 (BH3)-only proteins Puma and 
Noxa, and the activation of caspase-9 and Apaf-1-dependent mitochondrial apoptosis 
(Besch et al., 2009). 
 This study used an established model of HMPV infection in a mouse model 
lacking the type I IFN receptor (IFNAR-/- mice) to elucidate the role of type I IFN on the 
control of early viral replication and the pathogenesis of the virus. We found that IFNAR-/- 
mice had significantly higher viral titers early and at peak replication (Day 5) but were not 
impaired in the ability to clear HMPV. Mice challenged with virus 3 weeks after initial 
virus infection were immune to HMPV, and investigation into the neutralizing antibody 
(nAb) response showed higher nAb titer in IFNAR-/- animals. Higher levels of 
inflammatory cytokine transcripts and protein expression were also seen in WT, 
compared to transgenic animals, and the pulmonary dysfunction, measured by pulse 
oximetry, indicated significantly higher breathing effort in WT mice compared to IFNAR-/-. 
Analysis of histological lung sections from both groups showed that, corroborating our 
breath distension data, WT mice had significantly more lung inflammation during HMPV 
infection.  
 
Results 
 
Type I IFN signaling limits HMPV replication and spread, but also contributes to 
disease pathogenesis 
To characterize the role of IFNAR signaling in HMPV infection, we investigated 
the kinetics of HMPV replication in an IFNAR deficient (IFNAR-/-) transgenic mouse 
model.  IFNAR-/- mice exhibited significantly more infectious virus in the lungs at the peak 
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of HMPV infection (3 and 5 days post infection) compared to wild-type (WT) controls.  
However, viral clearance in IFNAR-/- mice was similar to WT animals, with decreasing 
virus titers at day 7 and no detectable virus by day 10 (Figure 3-1). WT and IFNAR-/- 
mice were challenged 22 days post-infection and neither had detectable viral replication.  
 
                    
Figure 3-1. Type I IFN signaling limits early HMPV replication, but is not necessary for 
clearance. Plaque assays to measure infectious HMPV titer in the lungs of WT and 
IFNAR-/- mice were performed on days 3, 5, 7, and 10 post-infection. A group of mice 
were challenged 3 weeks after initial infection, and plaque assays were performed 5 
days post-infection. N = 9 per group for day 3, 5, and 7, and an N = 5 for each group on 
days 10 and 26. Groups were compared with two-way ANOVA. *=P<0.05, ** = P <0 .02. 
 
  
To investigate the role of IFNAR in disease severity during HMPV infection, we 
first assessed weight loss and breath distension. IFNAR-/- mice showed significantly less 
weight loss compared to WT mice early after infection (Figure 3-2A). We utilized a 
mouse oximeter to quantify airway dysfunction, a key feature of severe LRI in humans 
(Hartert et al., 1999). Airway dysfunction and subsequent air trapping during HMPV 
infection leads to pulsus paradoxus, an exaggeration in the pulse volume during 
respiration as a result of increased breathing effort (Rebuck and Pengelly, 1973) which 
we quantified as breath distension. IFNAR-/- mice had significantly decreased breath 
A
3 5 7 10 21 26
1
2
3
4
5
H
M
PV
 T
ite
r (
Lo
g 1
0 
PF
U
/g
)
IFNAR-/-
**
**
WT
Days Post Infection
HMPV Challenge
 56 
distension compared to WT animals throughout the course of HMPV infection (Figure 3-
2B). Measurements from HMPV-infected IFNAR-/- mice were similar to those of 
uninfected WT mice (not shown). 
 
Figure 3-2. Type I IFN contributes to disease pathogenesis during HMPV infection. (A) 
WT and IFNAR-/- mice were weighed following infection with HMPV. Data are expressed 
as a % of average original body weight in each group; error bars represent the SEM. N = 
4 mice per group. (B) Breath distension of IFNAR+/+ mice and IFNAR-/- mice was 
measured using pulse oximetry following infection HMPV. N = 4-10 mice per day per 
group with at least two independent experiments. Groups were compared with unpaired t 
test or two-way ANOVA. *=P<0.05, ** = P <0 .02. 
 
 
Type I IFN signaling contributes to histopathological disease during HMPV 
infection, and IFNAR deficiency leads to lower levels of inflammatory cytokines 
To determine whether the marked lack of airway dysfunction in IFNAR-/- mice 
corresponded with histopathological disease, HMPV infected lungs from WT, IFNAR-/- 
mice, and uninfected control mice, were stained with H&E (Figure 3-3A) and periodic 
acid-Schiff (PAS), which preferentially stains polysaccharides in mucus (Figure 3-3B). 
HMPV-infected WT mice had increased inflammatory infiltrate compared to uninfected 
animals, while the lung architecture of infected IFNAR-/- mice appeared similar to 
uninfected controls with less inflammatory infiltrate (Figure 3-3A). Additionally, there  
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Figure 3-3. Type I IFN signaling contributes to histopathological disease during HMPV 
infection. Lungs from WT and IFNAR-/- mice 5 days after HMPV infection, or uninfected 
control animals, were stained with (A) H&E or (B) PAS (polysaccharide specific). Images 
of whole lungs from WT and knockout animals were taken at 1x using Aperio scope. 20x 
representative lung images are inset.  
 
appeared to be more mucus production in the lungs of WT as compared to IFNAR-/- mice 
(Figure 3-3B). 
Analysis of the lung histopathology using a formal scoring system identified 
significantly higher inflammation scores in the WT compared to IFNAR-/- groups (Figure 
3-4A). We also measured cytokine levels from whole lung homogenates collected from 
HMPV infected, as well as uninfected, WT and IFNAR-/- mice using RT-PCR.  In 
uninfected animals, cytokine levels are undetectable by this assay, or present at very 
low levels (data not shown). Therefore we compared infected WT to infected IFNAR-/- 
mice. These analyses revealed that TH1 cytokines, IFN-γ, IL-2 and IL-12, and IL-4 were  
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decreased in HMPV-infected IFNAR-/- mice as compared to HMPV-infected WT mice  
(Figure 3-4B). IFNγ protein levels were also measured by ELISA, and found to 
corroborate transcript data indicating higher inflammatory cytokines in WT mice (Figure 
3-4C) Together, these data suggest that IFNAR signaling contributes to disease 
pathogenesis in the lungs of HMPV infected mice. 
 
 
Figure 3-4. IFNAR deficiency leads to lower level of inflammatory cytokines. (A) A 
board-certified pathologist scored lungs stained with H&E from WT and IFNAR-/- mice 5 
days after HMPV infection, or uninfected control animals. N = 8 mice per group. (B) At 7 
days post-infection, lungs were harvested and cytokine levels were measured using RT-
PCR. Data are expressed as a ΔΔCT analysis between IFNAR and WT groups. N = 8 
mice per group. (C) At 7 days post-infection, lungs were harvested and IFNγ levels were 
determined using ELISA. N = 5 mice per group. Groups were analyzed by one-way 
ANOVA. Error bars represent SEM. *=P<0.05, ** = P <0 .02, **** = P < 0.0001. 
 
  
Figure 2: Type I IFN signaling contributes to histopathological 
disease during HMPV infection, and IFNAR deficiency leads to 
lower level of inflammatory cytokines. Lungs from WT and IFNAR-/- 
mice 5 days after HMPV infection, or uninfected control animals, were 
stained with (A) H&E or (B) PAS (polysaccharide specific). Images of 
whole lungs from WT and knockout animals were taken at 1x using 
Aperio scope. 20x representative lung images are inset. (C) Lung 
sections were scored by board-certified pathologist. N = 8 mice per 
group. (D) 7 days post-infection, lungs were harvested and cytokine 
OHYHOVZHUHPHDVXUHGXVLQJ573&5'DWDDUHH[SUHVVHGDVDǻǻ&7
analysis between IFNAR and WT groups. N = 8 mice per group. (E) 7 
days post-infection, lungs were harvested and IFNg levels were 
determined using ELISA. N = 5 mice per group. Error bars represent 
SEM. *=P<0.05, ** = P <0 .02, **** = P < 0.0001.
D
Uninfected HMPV Infected
IFN Il-2 IL-12 IL-4 IL-10
0
2
4
6
8
10
Fo
ld
 D
iff
er
en
ce
 o
f W
T 
vs
 IF
N
A
R
 K
O
 (2


C
T )
****
****
**
****
**
WT IFNAR-/-
0
200
400
600
800
IF
N
 
(p
g/
m
L)
*
E
WT IFNAR-/-
0.0
0.5
1.0
1.5
2.0
H
is
to
lo
gi
ca
l S
co
re
*
C A B
 
C 
 59 
Discussion 
We investigated early and late immune responses in IFNAR-deficient mice to 
elucidate the effect of IFNAR deficiency on the control and clearance of this virus in vivo. 
These data demonstrate that IFNAR signaling contributes to limiting both replication and 
spread of HMPV, similar to what has been observed in related viruses (Johansson et al., 
2007; Johnson et al., 2005; Schilte et al., 2010; Seo et al., 2011). One group found that 
for RSV in BALB/c mice, both type I and type II IFNs were important (Durbin et al., 2002; 
Johnson et al., 2005). IFNAR-/- mice displayed significantly higher levels of infectious 
virus and more HMPV antigen+ lung epithelial cells. By 10 days after HMPV infection, 
virus was not detectable by either plaque assays or direct staining of lung epithelial cells. 
We were not able to detect any HMPV+ CD11c+ lung macrophage/DCs at either 5 or 10 
days after HMPV infection. IFNAR-/- mice were immune to HMPV challenge after primary 
infection and had a higher serum titer of neutralizing antibody than WT mice. This 
increase in nAb titer could be due to increased viral antigen in IFNAR-/- mice, and 
potentially highlights an advantage to a more finely tuned modulator of the type I IFN 
pathway in using host innate immunity to prevent antigen loads from reaching levels 
necessary to develop sterilizing immunity. Moreover, these data show that in this model, 
type I IFN is not required to develop a fully protective response. 
 Recent studies have shown that RSV infection of IFNAR deficient mice leads to 
lower levels of inflammatory cytokines (Gautier et al., 2005; Goritzka et al., 2014; Rudd 
et al., 2007), and our data show that, similarly, IFNAR-/- mice infected with HMPV have 
fewer inflammatory cytokine transcripts. Histological analysis of infected animals showed 
significantly less lung inflammation in IFNAR-/- compared to WT mice, and IFNAR-/- mice 
had significantly less lung dysfunction and weight loss during infection, suggesting that 
IFNAR signaling contributes substantially to the major disease symptoms associated 
with HMPV infection (Edwards et al., 2013; Kolli et al., 2008; Williams et al., 2004). Thus, 
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although IFNAR signaling suppresses early viral replication, it is not essential for 
clearance of HMPV and contributes to disease pathogenesis. A recent paper focused on 
the response to HMPV in neonatal mice deficient in important adaptors of the innate 
cytokine response, IPS-1, IRF3 and IRF7, also corroborate our findings regarding the 
importance of the balance between protection and immune-induced pathogenesis for 
type I IFN (Spann et al., 2014). 
 
Materials and Methods 
 
Mice and Viruses. C57BL/6 (B6) mice were purchased from The Jackson Laboratory. 
IFN alpha/beta receptor deficient (IFNAR-/-) B6 mice were kindly provided by Dr. Herbert 
W. Virgin. All animals were bred and maintained in specific pathogen-free conditions 
under guidelines approved by the AAALAC and the Vanderbilt Institutional Animal Care 
and Use Committee. Six to twelve-week-old age- and gender-matched animals were 
used in all experiments. HMPV (pathogenic clinical strain TN/94-49, genotype A2) was 
grown and titered in LLC-MK2 cells as previously described (Williams et al., 2005c). For 
all experiments, mice were anesthetized with intraperitoneal ketamine-xylazine and 
infected intranasally with 1.5x106 PFU of HMPV. Serum was collected from WT and 
IFNAR-/- mice by submandibular venipuncture and was used in a plaque reduction assay 
to determine HMPV neutralizing antibody titers as previously described (Williams et al., 
2005c). The median of triplicate values for % HMPV neutralization for each animal of 
each genotype were plotted as a function of log2-transformed serum dilution factor and 
analyzed in a sigmoidal dose response curve to determine IC50. Nasal turbinates (NT) 
and lungs were collected for analysis and tissue viral titers measured by plaque titration 
as previously described (Williams et al., 2005c). For histopathology, the left lung was 
removed and inflated with 10% buffered formalin, paraffin-embedded, stained, and 
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analyzed using a formal scoring system in a group-blinded fashion by an experienced 
lung pathologist as previously described (Erickson et al., 2012). 
 
Pulse Oximetry. To measure breath distension, mice were anesthetized using an 
isofluorane:oxygen (2%:98%) (2 liters/min) mixture (VetEquip). Mice were secured on 
their backs and were given constant anesthesia during the procedure via a nosecone 
attachment. The right leg and thigh were shaved, and a thigh sensor was secured to the 
right thigh of each mouse and covered with a dark cloth to reduce ambient light. A pulse 
oximeter (MouseOx; Starr Life Sciences Corp.) was used to measure arterial O2 
saturation, heart rate, pulse rate, pulse distension, and breath distension every 0.1 
seconds (MouseOx software, version 4.0). Each mouse was monitored until sufficient 
data was collected in which all parameters were successfully measured, and only these 
data were used in analyses (1-2 minutes per mouse). Breath distension for each animal 
was calculated by averaging all measurements for each mouse per condition per 
genotype. 
 
Real-time RT-PCR. 200 µL of undiluted lung homogenate from infected or uninfected 
IFNAR+/+ and IFNAR-/- mice was lysed with an equal volume of RLT lysis buffer (Qiagen) 
and frozen at -20°C. Samples were thawed and RNA extracted using the MagNA Pure 
LC Total Nucleic Acid Isolation Kit (Roche Applied Sciences) on a MagNA Pure LC using 
the Total NA External Lysis protocol and stored at -80°C. Real-time RT-PCR was 
performed in 25µL reaction mixtures containing 5µL of extracted RNA on an ABI 
StepOnePlus Real-Time PCR System (Life Technologies/Applied Biosystems) using the 
AgPath-ID One-Step RT-PCR kit (Life Technologies/Applied Biosystems). For PD-L1, 
IFNγ, IL-2, IL-12, IL-4, and IL-10 gene expression, exon-spanning primers and probes 
were used according to the manufacturer’s instructions (Applied Biosystems/Ambion). All 
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values were normalized to the housekeeping gene HPRT. Cytokine transcript levels 
were low or undetectable in uninfected IFNAR-/- and WT mice. Therefore, experimental 
samples are reported as fold change in HMPV-infected WT mice compared to HMPV-
infected IFNAR-/- using the ΔΔCt method (Livak and Schmittgen, 2001). Samples with 
cycle threshold (Ct) values less than 40 were considered positive. 
 
Statistical Analyses. Data analysis was performed using Prism v4.0 (GraphPad 
Software). Groups were compared using unpaired t-test or one-way ANOVA with Tukey 
post-hoc test for multiple comparisons. P <0.05 was considered significant by 
convention. 
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CHAPTER IV 
 
Type I IFN signaling primes an efficient TCD8 response by  
expanding lung dendritic cells 
Work presented in this chapter also published in the Journal of Virology (Hastings et al., 2015) 
 
Introduction 
Type I IFN signaling is thought to be integral to the early immune response 
through the induction of anti-viral effector molecules (Barber, 2001; Biron, 2001; Sadler 
and Williams, 2008), and this pathway can modulate the adaptive immune response by 
contributing to both clonal expansion and maintenance of memory T cells as well as 
priming and differentiation of antigen presenting cells (APCs) (Havenar-Daughton et al., 
2006; Kolumam et al., 2005a; Le Bon and Tough, 2008; Luft et al., 1998). In addition, it 
has been shown that type I IFN can protect CD8+ T-cells from NK cell cytotoxicity, by a 
perforin-dependent mechanism (Xu et al., 2014). This NK cell-mediated death was 
demonstrated to depend on signaling through the natural cytotoxicity triggering receptor 
1 (NCR1) ligand, which is down regulated on CD8+ T cells in response to IFNAR 
signaling (Crouse et al., 2014). 
Recent data indicate that HMPV infection generates functionally impaired virus-
specific CD8+ T cells in the lungs as a result of signaling through the inhibitory receptor 
programmed death 1 (PD-1) (Erickson et al., 2012). PD-1, along with other inhibitory 
receptors, has been shown to be highly upregulated in both cancer and chronic viral 
infections (Fourcade et al., 2010; Jin et al., 2010a; Zhou et al., 2011), but little is known 
about the role of PD-1 in acute respiratory viral infections. The ligand for PD-1, 
programmed death ligand 1 (PD-L1), is expressed on professional APCs as well as 
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primary infected lung epithelial cells and is thought to be induced in an IFN-dependent 
manner (McNally et al., 2013; Muhlbauer et al., 2006).  
In this study, we used an established model of HMPV infection to demonstrate that 
genetic ablation of the IFN α receptor (IFNAR-/- mice) diminished the HMPV-specific 
CD8+ T cell response.  We found that although IFNAR-deficient animals were able to 
clear the virus after infection, and developed significantly higher antibody titers, they 
displayed lower overall disease and lung inflammation than wild-type animals.  Despite 
similar PD-1 expression and lower PD-L1 expression levels in IFNAR-/- mice during 
HMPV infection compared to wild-type mice, HMPV-specific CD8+ T cells were more 
impaired in IFNAR-/- than WT. T cell Ig- and mucin-domain–containing molecule–3 (TIM-
3) was significantly upregulated on HMPV-specific CD8+ T cells in the IFNAR-/- animals. 
Further investigation into the specific APC subsets in the lung during HMPV infection 
showed that alveolar macrophages do not rely on IFNAR signaling for expansion or the 
expression of PD-L1, but significantly fewer dendritic cells (DCs) were found in IFNAR-/- 
mice during HMPV infection. Both DCs and interstitial macrophages upregulated PD-L1 
in an IFNAR-dependent manner, while alveolar macrophages expressed high levels of 
the inhibitory ligand, compared to other lung APC subsets, in both infected and 
uninfected WT and IFNAR-/- mice. 
 
Results 
 
Lack of type I IFN signaling leads to higher serum nAb titers, and does not change 
CD8+ T cell or CD11c+ APC infiltration during HMPV infection  
The cytokine data presented in chapter III suggested a deficiency in the adaptive 
cellular immune response to HMPV infection in IFNAR-/- mice. To test the hypothesis 
that IFNAR signaling promotes adaptive immune responses to HMPV, we assessed 
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neutralizing antibody (nAb) titer and examined immune cells known to be important in 
the host response to respiratory viruses in the lungs of WT and IFNAR-/- mice. Twenty-
one days post-HMPV infection, serum was collected from previously infected WT and 
IFNAR-/- mice, and plaque neutralization assays were performed. IFNAR-/- mice 
possessed significantly higher nAb than WT (Figure 4-1), but, as indicated in Figure 3-1, 
both groups were immune to reinfection. 
                                
Figure 4-1. Lack of type I IFN signaling leads to higher serum nAb titers. WT C57BL/6 
mice and IFNAR knockout mice were infected with 106 PFU of HMPV and 21 days post-
infection animals were bled and serum was harvested. In vitro neutralization assays 
were performed in triplicate on LLC-MKC cells with increasing dilutions of previously 
infected mouse serum to determine IC50. Median values of % neut. for an N = 5 for each 
group were plotted as a function of the serum dilution factor to obtain best fit curves, and 
the IC50 for each curve was calculated. Groups were compared using one-way ANOVA 
with Tukey post-hoc test. Error bars represent SEM. * = P < 0.05. 
 
 
Next, we examined the infiltration of immune cells to the infected lung. Ten days 
post-HMPV infection, at the peak of the adaptive response, the total number of 
lymphocytes in the lungs of WT and IFNAR-/- mice was not significantly different (Figure 
4-2A). CD11c+ high lung cells, which are important for induction of innate and adaptive 
immune responses via viral antigen presentation, were significantly increased in both the 
IFNAR-/- and WT mice 10 days post infection compared to uninfected controls. However,  
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Figure 4-2. Type I IFN signaling does not change CD8+ T cell or CD11c+ dendritic cell 
infiltration during HMPV infection. Lungs from WT and IFNAR-/- mice 5 (A) or 10 days 
(B,C) after HMPV infection, or uninfected control animals, were harvested and analyzed 
by flow (A) Cells were gated on the small lymphocyte population, and the infiltration of 
these cells is shown as total number of lung lymphocytes. Specific staining of (B) CD11c 
and (C) CD8 allowed for the enumeration of CD8+ T-cells and CD11c+ dendritic cells. 
Total lung cell values, used to calculated number of cells, were measured by 
hemocytometer. Groups were compared using unpaired t test or one-way ANOVA with 
Tukey post-hoc test where appropriate. N = 4-15 mice per group with at least two 
independent experiments. Error bars represent SEM. * = P < 0.05, ***=P<0.002. 
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no statistically significant difference in CD11c+ high cell numbers was noted between the 
IFNAR-/- and WT mice (Figure 4-2B). CD8+ T cells were not significantly different in 
HMPV-infected mice when measured as a percentage of the total lymphocyte population 
after HMPV infection in WT or IFNAR-/- animals (Figure 4-2C). These data suggest that 
IFNAR signaling is not crucial for the recruitment of adaptive immune cells to the site of 
HMPV infection. 
 
Efficient development of a functional HMPV-specific CD8+ T cell response requires 
type I IFN signaling  
Given diminished respiratory tract pathology in IFNAR-/- mice (Chapter II) but similar 
recruitment of inflammatory cells to the lungs (Figure 4-2) upon HMPV infection, we 
wondered whether the functionality of the cells that reach the lung in IFNAR-/- mice 
differed compared to their WT counterparts.  To test this hypothesis, we first quantified 
the virus-specific component of the adaptive immune response.  To do this, we 
performed MHC tetramer staining for the immunodominant HMPV epitope F528-536 (F528) 
to enumerate HMPV epitope-specific cells. IFNAR-/- mice had significantly fewer F528- 
specific CD8+ T cells in the lungs compared with WT animals (Figure 4-3A). Next, we 
examined the functionality of these HMPV-specific cells using ex vivo peptide stimulation 
and intracellular cytokine staining (ICS) of lung lymphocytes collected 10 days post-
infection. A significantly lower fraction of HMPV-specific CD8+ T cells from IFNAR-/- mice 
produced IFNγ as compared to those from WT mice (Figure 4-3B). Based on previous 
studies showing that PD-1 signaling contributes to T cell impairment (Erickson et al., 
2012), we quantified PD-1 expression on both HMPV-specific and total CD8+ T 
lymphocytes. Although PD-1 was upregulated on HMPV-specific CD8+ T cells compared 
to bulk CD8+ T cells following viral infection, PD-1 expression on these HMPV-specific T 
cells was similar between IFNAR-/- and WT animals (Figure 4-3C). These data indicate 
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Figure 4-3. Efficient development of a functional HMPV-specific CD8+ T cell response 
requires type I IFN signaling. WT and IFNAR-/- mice were infected with HMPV, and 10 
days post-infection lungs were harvested and analyzed by flow cytometry. (A) An HMPV 
specific tetramer molecule was used to probe for virus specific CD8+ T cells in infected 
lungs for both groups. (B) Lymphocytes were also stimulated with an HMPV peptide in 
vitro, and intracellular cytokine staining was performed to analyze functionality of HMPV 
specific T-cells. (C) A specific antibody towards the inhibitory receptor PD-1 was used to 
examine its expression on bulk CD8+ T cells in infected and uninfected animals and 
HMPV specific CD8+ T cells from infected mice. Groups were compared using unpaired 
t-test or one-way ANOVA with Tukey post-hoc test where appropriate.  N = 9-15 mice 
from at least two independent experiments per group. Error bars represent SEM. 
*=P<0.05, ** = P <0.02, **** = P < 0.0001. 
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an important role for type I IFN signaling in the development of functional pulmonary 
CD8+ T cells, and show that the absence of IFNAR signaling does not directly affect PD-
1 expression on CD8+ T cells consistent with prior studies demonstrating TCR signaling 
as the primary determinant of PD-1 expression (Erickson et al., 2012).   
 
Type I IFN signaling limits the spread of HMPV in lung epithelial cells 
 To further examine the infected lung epithelium in the mouse model, we 
developed an assay for the isolation and analysis of lung epithelial cells using flow 
cytometry. The average number of HMPV-infected lung cells in IFNAR-/- and WT mice 
was analyzed using a monoclonal antibody to identify EPCAM+ lung epithelial cells, and 
a polyclonal anti-HMPV sera to identify HMPV+/EPCAM+ cells (Figure 4-4A).  IFNAR-/- 
animals had a significantly higher percentage of HMPV+/EPCAM+ lung epithelial cells on 
day 5 post-infection (Figure 4-4B). No viral antigen was detected by flow cytometry in 
epithelial cell populations at 10 days post infection or in CD11c+ high lung dendritic cells 
(DCs) at either 5 or 10 days post infection (data not shown). These data show that type I 
IFN is important in controlling not only replication as shown in figure 1, but also viral 
spread in the lung. 
 
Expression of PD-L1 is driven by, but not dependent on, type I IFN signaling in 
lung epithelial cells and CD11c+ cells  
Since the expression of PD-1 was not different on virus-specific IFNAR-/- TCD8 compared 
to WT, we wondered whether the differences in CTL functionality we observed could be 
due to altered expression of the PD-1 ligand, PD-L1. Prior work has indicated that the 
promoter of PD-L1 contains IFN regulatory elements, and that IFN signaling can 
promote PD-L1 expression on epithelial and endothelial cells (Eppihimer et al., 2002; 
Lee et al., 2006b). We therefore quantified the expression of PD-L1 in respiratory 
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Figure 4-4. Type I IFN limits the spread of HMPV in lung epithelial cells. (A) Cells were 
stained for EPCAM and HMPV. Dead cells were excluded using an amine reactive dye. 
All analysis was done directly ex vivo. For analysis of HMPV+ EPCAM+ cells 
background staining of HMPV for uninfected mouse lung cells was determined and 
subtracted from experimental values. For analysis of PD-L1 expression, cells were 
probed with an isotype control antibody and this background was subtracted from 
experimental values. (B) At day 5 after HMPV infection, lungs were harvested and 
stained for EPCAM positive lung epithelial cells. These cells were then probed for HMPV 
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antigen with a polyclonal antibody and fluorescent secondary, and % HMPV-infected 
EPCAM+ cells for each group was measured using flow cytometry. N = 4-10 mice per 
day per group with at least two independent experiments. Groups were compared with 
unpaired Student’s t test or two-way ANOVA. *=P<0.05. 
 
epithelial cells and CD11c high cells on day 5 after HMPV infection. PD-L1 was 
significantly upregulated on both virus antigen-positive and virus antigen-negative lung 
epithelial cells in both WT and IFNAR-/- mice (Figure 4-5A). However, PD-L1 expression 
was significantly lower in IFNAR-/- animals as compared to WT animals. By 10 days 
post-infection, no differences were observed between the levels of PD-L1 expression in 
lung epithelial cells in HMPV infected WT compared to IFNAR-/- mice (Figure 4-5B) or in 
total PD-L1 transcript levels in the lungs of these animals (Figure 4-6B), although the 
PD-L1 levels on epithelial cells were still significantly higher in both groups than 
uninfected mice. These results indicate that while IFNAR signaling can lead to increased 
expression of PD-L1, it is not an exclusive regulator of this ligand, and other signaling 
pathways can upregulate PD-L1.  
PD-L1 expression on bulk CD11c+ lung cells 5 days post- HMPV infection in both 
WT and IFNAR-/- mice increased slightly compared to uninfected animals, but did not 
reach significance, and no difference was detected between groups (Figure 4-5C).  On 
day 10 post-infection, PD-L1 expression on CD11c+ cells was indistinguishable between 
infected and uninfected animals in both WT and IFNAR-/- mice (Figure 4-5D). Later 
analyses into the subsets of CD11c+ cells in the lung, found in figures 4-8-10), 
demonstrate that, in fact, this population of cells is heterogeneous, and the discrete APC 
subsets in this gate have significant differences in their baseline expression of PD-L1 
and the upregulation of this inhibitory ligand upon HMPV infection. 
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Figure 4-5. Expression of PD-L1 is driven by, but not dependent on, type I IFN signaling 
in lung epithelial cells and CD11c+ dendritic cells. WT and IFNAR-/- mice were infected 
with HMPV, and after (A,C) 5 or (B,D) 10 days post-infection lungs were harvested, 
along with uninfected control (HMPV-), and analyzed by flow cytometry. Specific staining 
of (A,B) EPCAM and (C,D) CD11c allowed for the analysis of EPCAM+ lung epithelium 
and CD11c+ dendritic cells. EPCAM+ cells at day 5 were also probed for HMPV antigen 
with a polyclonal antibody and fluorescent secondary to enable gating of infected (HMPV 
Antigen +) and uninfected (HMPV Antigen -) cells. A specific antibody towards the 
inhibitory ligand PD-L1 was used to measure its expression on all epithelial and dendritic 
cell populations at each time point. Groups were compared using unpaired Student’s t 
test or one-way ANOVA with Tukey post-hoc test where appropriate. N = 4-9 mice per 
experimental group representative of at least two independent experiments. Error bars 
represent SEM. *=P<0.05, ** = P < 0.02, ***=P<0.002, **** = P < 0.0001. 
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Functional impairment of HMPV specific CD8+ T cells is not due to Treg infiltration 
but rather corresponds to expression of the inhibitory receptor TIM3  
IFNAR signaling has been shown to affect the development and recruitment of 
CD4+ regulatory T (Treg) cells, but the data are unclear as to whether that effect is 
positive or negative (de Andres et al., 2007; Golding et al., 2010; Namdar et al., 2010; 
Srivastava et al., 2014a). Tregs possess a myriad of anti-inflammatory properties, 
including suppressing virus-specific CTLs during LRI (Fulton et al., 2010). We therefore 
quantified Treg infiltration into infected lungs of IFNAR-/- and WT mice at day 5 post-
HMPV infection. We found significant infiltration of Tregs in the lungs of infected WT 
mice but not in IFNAR-/- animals (Figure 4-6A). These results help explain the lower IL-10 
transcript level we observed in IFNAR-/- mice compared to WT mice (Chapter II), and 
suggest that IFNAR signaling is important for the infiltration of Tregs during HMPV 
infection. However, recruitment of Tregs does not appear to be responsible for the 
impaired CD8+ T cell phenotype.  
We analyzed HMPV-specific CD8+ T cells 10 days post-infection for the 
expression of the other known inhibitory receptors TIM-3, LAG-3, and 2B4. A significant 
upregulation of 2B4 (Figure 4-7A) was observed on HMPV-specific CD8+ T cells, 
although there were no differences between WT and IFNAR deficient mice. No 
significant upregulation of LAG-3 (Figure 4-7B) was observed on HMPV-specific CD8+ T 
cells in either IFNAR-/- or WT animals. However, we found that the percentage of TIM-3+ 
HMPV- specific CD8+ T cells was significantly higher in IFNAR-/- compared with WT mice 
(Figure 4-7C). There were significantly more TIM3+ HMPV-specific CD8+ T cells in both 
IFNAR-/- and WT mice than either naïve CD8+ T cells from uninfected animals or non-
specific CD8+ T cells from HMPV-infected WT mice (Figure 4-7C).These data indicate 
that upregulation of the inhibitory receptor TIM-3 is associated with an exhausted 
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phenotype observed in HMPV-specific CD8+ T cells in the context of an IFNAR 
deficiency. 
 
 
 
 
 
Figure 4-6.  Functional impairment of HMPV specific CTLs is not due to Treg infiltration 
or total PD-L1 transcript. WT and IFNAR-/- mice were infected with HMPV, and after (A) 
five or (B) seven days post-infection lungs were harvested and analyzed by flow 
cytometry or RT-PCR.  (A) To identify CD4+ regulatory T cells, specific antibodies 
towards CD4, FOXP3, and CD25 were used in uninfected and infected mice. (B) Lungs 
were processed and RT-PCR was used to measure PD-L1 transcript levels in WT and 
IFNAR-/- mice. Data are expressed as a 2^ΔΔCT analysis between IFNAR-/- and WT 
groups. Groups were compared using one-way ANOVA with post-hoc Tukey test. N = 4-
7 mice per experimental group with two independent experiment.  Error bars represent 
SEM. ***=P<0.002. 
 
Subsets of lung APCs are differentially affected by IFNAR signaling during HMPV 
infection  
 Five distinct categories of antigen presenting cells located in the mouse lung 
have been classified based upon their surface marker expression (Figure 4-8) as well as 
their ability to present viral epitopes to CD8+ T cells during infection (Misharin et al., 
2013).  Both alveolar macrophages and dendritic cells (DCs) (Figure 4-8, top right) 
express high levels of CD11c but can be distinguished from each other by the higher 
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Figure 4-7. : Impairment of HMPV specific CTLs does not correspond with the 
expression of 2B4 or LAG3, but rather with expression of inhibitory receptor TIM3. WT 
and IFNAR-/- mice were infected with HMPV, and after ten days post-infection lungs 
were harvested and analyzed by flow cytometry. Specific staining of bulk CD8+ T cells in 
uninfected and infected mice and HMPV specific CD8+ T-cells in infected animals with 
antibodies toward the inhibitory markers (A) 2B4, (B) LAG3, and (C) TIM3 was used to 
determine %inhibitory receptor positive cells in HMPV specific, as well as non-specific, 
CD8+ T-cells. Groups were compared using one-way ANOVA with post-hoc Tukey test. 
N = 4-5 mice per experimental group with two independent experiment.  Error bars 
represent SEM. ***=P<0.002, **** = P < 0.0001. 
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level of MHC class II expression in the DC subset (Kirby et al., 2006).  DCs in the lungs 
can also be broken down into two groups, CD11b+ and CD11b- DCs (Figure 4-8, bottom 
right), which have also been shown to express CD103 (Furuhashi et al., 2012). 
Plasmacytoid dendritic cells (pDCs) express low levels of both CD11c and MHC class II 
(Figure 4-8, top right). Interstitial macrophages (Figure 4-8, bottom left) in the lung do not 
express CD11c, but do express high levels of CD11b and moderate levels of MHC class 
II. 
 
Figure 4-8. Gating strategies for dendritic cell and macrophage analysis. Cells were 
stained with CD11c, CD11b, and MHC Class II. Dead cells were excluded using an 
amine reactive dye. All analyses were done directly ex vivo. For analysis of PD-L1 
expression, cells were probed with an isotype control antibody and this background was 
subtracted from experimental values. 
 
During HMPV infection both WT and IFNAR-/- mice display a significant increase 
in alveolar macrophages compared to uninfected animals in each group (Figure 4-9A), 
but the number of DCs proved to be IFN-dependent, as the number of pDCs as well as 
conventional DCs in the lungs of infected IFNAR-/- animals equaled the number in 
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uninfected mice and was significantly fewer than HMPV-infected WT mice (Figure 4-9C 
and D). In addition, significantly more CD11b+ DCs were present in the lungs of HMPV- 
infected WT mice compared to uninfected WT or IFNAR-/- mice and infected IFNAR-/- 
mice (Figure 4-9E). No significant differences were seen in the number of CD11b- DCs 
(Figure 4-9F) or interstitial macrophages between uninfected and infected or WT and 
IFNAR-/- (Figure 4-9B). These data show that type I IFN is crucial for the recruitment 
and/or proliferation of DCs in infected mouse lungs, but that alveolar macrophages are 
unaffected by a lack of IFNAR signaling during HMPV infection. 
 
 
IFNAR signaling affects the expression of PD-L1 on DCs and interstitial 
macrophages, but alveolar macrophages constitutively express high levels of PD-
L1 regardless of the presence of IFNAR 
 To determine the ability for various subtypes of lung APCs to signal through the 
inhibitory PD1:PDL1 pathway, we analyzed the fraction of cells expressing the inhibitory 
ligand PD-L1 during HMPV infection. We found that nearly all alveolar macrophages in 
uninfected and infected WT and IFNAR-/- mice expressed PD-L1 (Figure 4-10A). In 
contrast, the percentage of cells expressing PD-L1 on all DC subsets, as well as 
interstitial macrophages, during HMPV infection was significantly lower in infected 
IFNAR-/- mice (Figures 4-10B-E). In DCs and interstitial macrophages of WT mice a 
significant increase in the fraction of PDL1+ cells was observed in HMPV-infected 
compared to uninfected mice, but upregulation of PD-L1 appears to be IFNAR 
dependent, as IFNAR-/- mice displayed no difference in PD-L1 expression on these cells 
during infection (Figures 4-10B-E).   
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Figure 4-9. Subsets of lung APCs are differentially affected by type I IFN signaling 
during HMPV infection. WT and IFNAR-/- mice were infected with HMPV, and after five 
days post-infection lungs were harvested and analyzed by flow cytometry. Cells were 
gated according to the gating strategy outlined in figure 4-8 as (A) CD11c+ MHCIImid 
alveolar macrophages, (B) CD11c- MHCIImid CD11b+ interstitial macrophages, (C) 
CD11clo MHCIIlo plasmacytoid dendritic cells (D) CD11c+ MHCIIhigh dendritic cells, (E) 
CD11c+ MHCIIhigh CD11b+ dendritic cells and (F) CD11c+ MHCIIhigh CD11b- dendritic 
cells. Total lung cell values, used to calculated number of cells, were measured by 
hemocytometer. Groups were compared using unpaired Student’s t test or one-way 
ANOVA with Tukey post-hoc test where appropriate. N = 4-9 mice per experimental 
group representative of at least two independent experiments. Error bars represent 
SEM. *=P<0.05, ** = P < 0.02, ***=P<0.002, **** = P < 0.0001. 
 
 
Additionally, the level of PD-L1 expression on alveolar macrophages as 
measured by mean fluorescence intensity was significantly higher than the other APC 
subsets (Figure 4-11). Type I IFN appears to be indispensable for PD-L1 expression on 
DCs and interstitial macrophages during HMPV infection, but my data suggest that 
alveolar macrophages constitutively express this inhibitory ligand at high levels in both 
uninfected and infected lungs. 
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Figure 4-10. Type I IFN signaling drives the expression of PD-L1 on DCs and interstitial 
macrophages, but alveolar macrophages constitutively express high levels of PD-L1. WT 
and IFNAR-/- mice were infected with HMPV, and after five days post-infection lungs 
were harvested and analyzed by flow cytometry. (A) CD11c+ MHCIImid alveolar 
macrophages, (B) CD11c+ MHCIIhigh CD11b+ dendritic cells, (C) CD11c+ MHCIIhigh 
CD11b- dendritic cells, and (D) CD11c- MHCIImid CD11b+ interstitial macrophages were 
probed with a specific anitbody for the inhibitory ligand PD-L1. An isotype control 
antibody was used to draw gates to measure the percentage of cells expressing this 
marker. Groups were compared using unpaired t test or one-way ANOVA with Tukey 
post-hoc test where appropriate. N = 4-9 mice per experimental group representative of 
at least two independent experiments. Error bars represent SEM. *=P<0.05, ** = P < 
0.02, **** = P < 0.0001. 
 
Elimination of IFNAR in hematopoietic or non-hematopoietic cells leads to less 
pathogenesis, while IFNAR expression on bone marrow-derived cells is important 
for a potent TCD8 response 
In order to assess the importance of type I IFN signaling in the lung tissue 
compared to the hematopoietic compartment, we irradiated WT and IFNAR-/- mice and 
performed reciprocal bone marrow transfers between the two groups. In this way, we  
E D 
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Figure 4-11. Alveolar macrophages express higher levels of PD-L1 than other APC 
subsets regardless of IFNAR signaling. WT and IFNAR-/- mice were infected with HMPV, 
and after five days post-infection lungs were harvested and analyzed by flow cytometry. 
PD-L1+ (A,F) CD11c+ MHCIImid alveolar macrophages, (B,F) CD11c- MHCIImid CD11b+ 
interstitial macrophages, (C,F) CD11clo MHCIIlo plasmacytoid dendritic cells, (D,F) 
CD11c+ MHCIIhigh CD11b+ dendritic cells, and (E,F) CD11c+ MHCIIhigh CD11b- dendritic 
cells was measured with a specific anitbody for the inhibitory ligand. (F) An isotype 
control antibody was used to normalize its expression level as measured by MFI on four 
subtypes of lung APCs. Groups were compared using unpaired Student’s t test or one-
way ANOVA with Tukey post-hoc test where appropriate. N = 4-9 mice per experimental 
group representative of at least two independent experiments. Error bars represent 
SEM. *=P<0.05, ** = P < 0.02, **** = P < 0.0001. 
 
derived mice that expressed IFNAR on either the bone-marrow derived cells only or only 
on non-hematopoietic cells. When these mice were infected with HMPV, neither mice 
lacking IFNAR on tissues nor those with type I IFN in bone marrow-derived cells reached 
the level of lung dysfunction, as measured by breath distension, observed in WT mice 
(Figure 4-12). The highest amount of pathogenesis occurs at day 9, suggesting that type 
I and type II IFN contributes to this disease state. The elimination of type I IFN signaling 
in either cell compartment is capable of ameliorating the level of pathogenesis seen in 
WT animals, so we analyzed the functionality of TCD8 response in both of these models. 
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Figure 4-12. Expression of IFNAR on both hematopoietic and non-hematopoietic cells 
contributes to lung dysfunction. Breath distension of IFNAR+/+, IFNAR-/- mice, IFNAR-/- 
BM or IFNAR-/- tissue was measured using pulse oximetry following infection HMPV. N = 
3 mice per day per group with one experiment.   
 
The magnitude of the HMPV-specific TCD8 response is restored to more WT 
levels in mice reconstituted with IFNAR+/+ bone marrow as measured by the percentage 
of HMPV F528-specific TET+ in infected lungs at day 10 (Figure 4-13A) or by the 
absolute number of these cells (Figure 4-13B). We treated these same cells with the 
F528 peptide for 6 hours, and measured their ability to express IFNγ by intracellular 
cytokine staining. We found that similar to the size of the HMPV-specific response, the 
functionality of this response also relies on type I IFN signaling in hematopoietic cells 
(Figure 4-13C). 
 
The expression of PD-L1 increases significantly on CD11b+ and CD11b- DCs on 
day 10 of HMPV infection, regardless of type I IFN expression 
On day 10 post HMPV-infection, we measured frequency of the APC subsets 
and observed that, unlike day 5, there was no differences between most groups (Figure  
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Figure 4-13. Type I IFN signaling in bone marrow-derived cells is crucial for a robust 
and functional TCD8 response. (A) An HMPV specific tetramer molecule was used to 
probe for virus specific CD8+ T cells in infected lungs for all groups. (B) Lymphocytes 
were also stimulated with an HMPV peptide in vitro, and intracellular cytokine staining 
was performed to analyze functionality of HMPV specific T-cells. N = 3-6 mice per day 
per group with one experiment. 
 
4-14A-F), likely due to type II IFN signaling from infiltrating TCD8. There were lower levels 
of alveolar macrophages in mice reconstituted with IFNAR-/- bone marrow (Figure 4-14A) 
and a concurrent increase in the level of interstitial macrophages (Figure 4-14B), The 
expression of PD-L1 on alveolar and interstitial macrophages, as well as on pDCs, was 
relatively homogenous and not different between groups (Figure 4-15). 
C
BA
WT IFNAR-/- BM Tissue
0
25
50
75
100
125
%
Fu
nc
tio
na
l H
M
PV
-S
pe
ci
fic
 L
un
g 
C
D
8+
 C
el
ls
 (%
IF
N
+
/%
Te
t+
)
IFNAR-/-
WT IFNAR-/- BM Tissue
0
20000
40000
60000
# 
Te
t+
 C
D
8 
C
el
ls
IFNAR-/-
WT IFNAR-/- BM Tissue
0
1
2
3
4
5
HM
PV
-S
pe
ci
fic
 L
un
g 
CD
8+
 C
el
ls
 (%
)
IFNAR-/-
 83 
  
Figure 4-14. Type I IFN signaling is not important to APC expansion at day 10 post 
HMPV-infection. WT and IFNAR-/- mice as well as the reciprocal bone marrow chimeras 
were infected with HMPV, and after ten days post-infection lungs were harvested and 
analyzed by flow cytometry. Cells were gated according to the gating strategy outlined in 
figure 4-8 as (A) CD11c+ MHCIImid alveolar macrophages, (B) CD11c- MHCIImid CD11b+ 
interstitial macrophages, (C) CD11clo MHCIIlo plasmacytoid dendritic cells (D) CD11c+ 
MHCIIhigh dendritic cells, (E) CD11c+ MHCIIhigh CD11b+ dendritic cells and (F) CD11c+ 
MHCIIhigh CD11b- dendritic cells. Total lung cell values, used to calculated number of 
cells, were measured by hemocytometer. N = 3-6 with one independent experiment. 
 
 
Interestingly, when the level of this inhibitory ligand was measured on either 
CD11b+ or CD11b- DCs, a distinct bimodal distribution of PD-L1 expression level was 
observed (Figure 4-16A and B). The level of PD-L1 expression on the higher expressing 
subset of cells on either CD11b+ or CD11b- DCs was equal or higher than the level seen 
on alveolar macrophages (Figure 4-17). The ratio of PD-L1lo vs. PD-L1high expressing 
DCs is distinctly different for each subset, CD11b+ DCs displayed approximately equal 
percentage of each while CD11b- DCs have over 80% of PD-L1+ cells in the higher 
expressing group (Figure 4-16C and D).  
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Figure 4-15. Type I IFN signaling does not contribute to PD-L1 expression on lung APC 
subsets at day 10 HMPV infection. WT, IFNAR-/- mice as well as the reciprocal bone 
marrow chimeras were infected with HMPV, and after ten days post-infection lungs were 
harvested and analyzed by flow cytometry. PD-L1+ (A) CD11c+ MHCIImid alveolar 
macrophages, (B) CD11c- MHCIImid CD11b+ interstitial macrophages, (C) CD11clo 
MHCIIlo plasmacytoid dendritic cells, (D) CD11c+ MHCIIhigh CD11b+ dendritic cells, and 
(E) CD11c+ MHCIIhigh CD11b- dendritic cells, was measured with a specific anitbody for 
the inhibitory ligand. N = 3-6 mice per group with 1 independent experiment.  
 
 
Discussion  
 IFNAR-/- mice had a significant defect in the number of HMPV-specific 
CD8+ T cells, consistent with previous data suggesting that IFNAR signaling plays a role 
in the clonal expansion of CD8+ T cells (Kolumam et al., 2005a) and in the maturation 
and priming of APCs (Azuma et al., 2012; Ehlers and Ravetch, 2007; Kadowaki and Liu, 
2002; Luft et al., 1998). Virus-specific CD8+ T cells become functionally impaired in the 
lungs during acute viral LRI, including HMPV, and this functional defect is predominantly 
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Figure 4-16. Bimodal distribution of PD-L1 expression in conventional DC subset on day 
10 HMPV infection. WT, IFNAR-/- and reciprocal bone marrow chimera mice were 
infected with HMPV, and lungs were harvested at day 10. (A,C) CD11c+ MHCIIhigh 
CD11b+ dendritic cells and (B,D) CD11c+ MHCIIhigh CD11b- dendritic cells were gated 
according to strategy in figure 4-8 and probed for PD-L1 level with a specific antibody. N 
= 3-6 mice with 1 independent experiment. 
 
driven by inhibitory signaling from the PD-1 receptor and its ligand, PD-L1 (Erickson et 
al., 2012). Because interferons have been identified as inducing expression of PD-L1 
(Eppihimer et al., 2002; Lee et al., 2006b; Muhlbauer et al., 2006), we expected to 
observe restoration of T cell functionality in our IFNAR-/- model. However, we found that 
the functional impairment of CD8+ T cells in IFNAR-/- mice was actually significantly 
increased. Importantly, this difference in impairment was not associated with increased 
expression of PD-1. In addition, while PD-L1 expression levels in the lung were 
upregulated in both WT and IFNAR-/- mice, IFNAR-/- animals exhibited lower PD-L1 
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Figure 4-17. Expression of PD-L1 is highest in alveolar macrophage and conventional 
dendritic cells at day 10 HMPV infection. WT, IFNAR-/- and reciprocal bone marrow 
chimera mice were infected with HMPV, and lungs were harvested at day 10. Cells were 
gated according to the gating strategy outlined in figure 4-8 as CD11c+ MHCIImid 
alveolar macrophages, CD11c- MHCIImid CD11b+ interstitial macrophages, CD11clo 
MHCIIlo plasmacytoid dendritic cells, CD11c+ MHCIIhigh dendritic cells, CD11c+ 
MHCIIhigh CD11b+ dendritic cells and CD11c+ MHCIIhigh CD11b- dendritic cells, and 
probed for PD-L1 with a specific antibody. An isotype control antibody was used to 
normalize expression as measured by MFI. N = 3-6 mice per group with 1 independent 
experiment.  
 
levels than WT animals in both lung epithelial and CD11+ cells. Thus, although PD-L1 
expression on both lung epithelial and CD11c+ cells was affected by IFNAR signaling, 
these differences were not sufficient to explain the reduction in the CD8+ T cell 
functionality observed in IFNAR-/- mice.  
To date there are conflicting studies on the impact of IFNAR signaling on Tregs.  
Some groups have shown a negative impact of IFNAR signaling on the development of 
Tregs (Golding et al., 2010; Srivastava et al., 2014a), but others have shown that 
treatment with type I IFN can lead to higher Treg numbers (de Andres et al., 2007; 
Namdar et al., 2010). Tregs can secrete suppressive cytokines, such as IL-10, to limit 
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the functionality of CD4+ and CD8+ T-lymphocytes during respiratory viral infections 
(Fulton et al., 2010), but we actually observed fewer Tregs and lower IL-10 gene 
expression in IFNAR-/- mice indicating a positive role for IFNAR signaling in Treg 
recruitment or proliferation. 
 Other inhibitory T cell receptors including LAG-3 (Workman and Vignali, 2005), 
2B4 (Chlewicki et al., 2008), and TIM-3 (Sakuishi et al., 2011) contribute to CD8+ T cell 
exhaustion during chronic infection, with expression of multiple receptors increasing the 
exhaustion phenotype (Nirschl and Drake, 2013; Odorizzi and Wherry, 2012). While we 
saw no differences in LAG-3 and 2B4 expression during HMPV infection, HMPV-specific 
CD8+ T cells from IFNAR-/- mice were significantly more likely to express the TIM-3 
receptor. TIM-3 is a member of the Tim family of molecules containing a N-terminal IgV 
domain, a mucin domain, a transmembrane domain, and a tail extending to the 
cytoplasm (Kuchroo et al., 2003). This molecule is capable of binding to its ligand, 
galectin-9, and inducing suppressive signals in both CD4+ and CD8+ T cells (Cao et al., 
2007; Santiago et al., 2007; Zhu et al., 2005). This interaction has been associated with 
peripheral tolerance (Sabatos et al., 2003).  Recent studies have revealed the 
importance of TIM-3 in cancer (Fourcade et al., 2010; Zhou et al., 2011) and chronic 
viral disease (Golden-Mason et al., 2009; Jin et al., 2010a; McMahan et al., 2010; Ngiow 
et al., 2011; Sakuishi et al., 2010; Sehrawat et al., 2010). Our data shows that in the 
context of respiratory viral infections, the diminished function of HMPV-specific CD8+ T 
cells in IFNAR deficient mice corresponds to increased expression of the inhibitory 
receptor TIM-3. Since HMPV and other viruses display the ability to downregulate 
IFNAR signaling, TIM-3 may provide an attractive target for therapeutic intervention 
during HMPV infection.  
 Alveolar macrophages and dendritic cells both express the cell surface marker 
CD11c, and these cells types along with interstitial macrophages are crucial antigen 
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presenting cells in the lung (Misharin et al., 2013). In WT mice, we observed an increase 
in both alveolar macrophages and dendritic cells during HMPV infection, but in mice 
lacking IFNAR signaling there was a significant defect in the amount of dendritic cells, 
but not alveolar macrophages, in the lung during infection.  Analysis of PD-L1 
expression in these subsets indicated that alveolar macrophages constitutively express 
high levels of this inhibitory ligand, while dendritic cells and interstitial macrophages rely 
on IFNAR signaling for PD-L1 expression. Reflecting this, the total expression level of 
PD-L1 was significantly lower in DCs and interstitial macrophages from IFNAR-/- than 
WT mice. Thus, the defect in the number of PD-L1-low DCs during viral infection of 
IFNAR-/- mice leads to a greater ratio of APCs expressing high levels of PD-L1 (i.e., 
alveolar macrophages) in infected lungs, potentially explaining the decrease in CD8+ T 
cell functionality observed in IFNAR-/- mice. Further, the decrease in total APCs was 
consistent with the defect in HMPV-specific CD8+ T cell numbers, suggesting a global 
effect of the lack of type I IFN. Additionally, our data suggest that due to intrinsic 
differences in PD-L1 expression, dendritic cells produce a more functional CD8+ T cell 
response compared to alveolar macrophages. These data corroborate previous findings 
on the importance of dendritic cells to the immune response in the respiratory tract (Kim 
and Braciale, 2009). 
 Preliminary data on the importance of type I IFN in the hematopoietic versus non-
hematopoietic cells presented here show that the contribution of IFNAR in bone marrow 
derived cells is crucially important for the development of a TCD8 response. Type I IFN 
signaling on tissue did not contribute to this impairment, but it did play a role in the 
development of disease pathogenesis in this model. This phenomenon is likely due to 
the lack of IFNAR signaling early in infection protecting IFNAR-/- tissue and IFNAR-/- 
mice, and the impairment in TCD8 expression of type II IFN by IFNAR-/- mice and those 
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with IFNAR-/- BM. This suggests an additive role in disease pathogenesis for type I and II 
IFNs.  
 We observed that on day 10 the number and PD-L1 expression level of APC 
subsets were not markedly different regardless of IFNAR deficiency. Intriguingly though, 
plasmacytoid DCs were higher only in WT mice on day 10. These cells have been 
shown to specifically detect HMPV (Banos-Lara Mdel et al., 2013) and contributes to 
RSV disease pathogenesis in mice (Smit et al., 2008), so the higher levels of pDCs 
could be related to the increase in lung dysfunction observed in this group. Conventional 
DCs exhibited the ability to increase expression of PD-L1 to levels comparable to those 
found on alveolar macrophages at day 10 post infection, and this upregulation appears 
to comprise two distinct subsets of cells, one expressing high levels and the other 
expressing relatively lower levels of PD-L1. In CD11b+ cells, these two subsets are 
found at approximately the same level, but in CD11b- DCs, we showed much higher 
percentages of PD-L1high cells. As discussed earlier, CD103+ DCs, found in the CD11b- 
group of DCs, have been shown to be particularly adept at generating a functional TCD8 
response, so this increase in PD-L1 could be directly related to interactions between 
these cells and functional TCD8. 
 Cross-presentation of viral peptides by APCs is an essential part of the 
generation of a specific TCD8 response [Yu, 2008 #1080], and IFN signaling is capable of 
driving cross-presentation in these cells [Belz, 2002 #610]. This defect is also likely a 
major factor in the observed defect in the development of an HMPV-specific TCD8 
response in IFNAR-/- mice. It should be noted that these experiments used the C57BL/6 
mouse model for HMPV infection. This model is well established as a good model for 
viral replication and the development and assessment of adaptive immune responses 
(Erickson et al., 2012; Erickson et al., 2014b), but other groups studying HMPV use the 
BALB/c mouse model, and some differences do exist (Alvarez and Tripp, 2005; Melendi 
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et al., 2007). Specifically related to T cell polarization, C57BL/6 mice have a TH1 bias, 
dominated by the expression of IFNγ, IL-2 and TNFα, while BALBC mice show a TH2 
bias, marked by expression of IL-4, IL-5, IL-6, IL-9, IL-10, and IL13 along with a strong 
antibody response (Gessner et al., 1993; Locksley et al., 1987; Romagnani, 2000). Both 
of these models have provided valuable information towards understanding human 
disease, but the differences should be taken into consideration. 
 Taken together, our data reveal an important role for type I interferon signaling in 
both the innate and adaptive host control of HMPV as well as in disease pathogenesis. 
We demonstrate that signaling through IFNAR significantly contributes to increased 
inflammatory lung disease during HMPV infection, and therapeutics targeting this 
pathway may provide a way to mitigate disease symptoms. Because IFNAR signaling 
promotes dendritic cell expansion during early HMPV replication, elimination of this 
pathway results in a defect in the development of an efficient and effective CD8+ T cell 
response. These findings expand our understanding of the importance of IFNAR 
signaling in HMPV replication and disease, as well as suggest a mechanism for IFNAR-
independent impairment of the CD8+ T cell response. 
 
Materials and Methods 
 
Mice and Viruses. C57BL/6 (B6) mice were purchased from The Jackson Laboratory. 
IFN alpha/beta receptor deficient (IFNAR-/-) B6 mice were kindly provided by Dr. Herbert 
W. Virgin. All animals were bred and maintained in specific pathogen-free conditions 
under guidelines approved by the AAALAC and the Vanderbilt Institutional Animal Care 
and Use Committee. Six to twelve-week-old age- and gender-matched animals were 
used in all experiments. HMPV (pathogenic clinical strain TN/94-49, genotype A2) was 
grown and titered in LLC-MK2 cells as previously described (Williams et al., 2005c). For 
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sucrose purified virus, HMPV TN/94-49 used in previous experiments was purified 
through a sucrose gradient as previously described (Cox et al., 2014). For all 
experiments, mice were anesthetized with intraperitoneal ketamine-xylazine and infected 
intranasally with 1.5x106 PFU of HMPV. Serum was collected from WT and IFNAR-/- 
mice by submandibular venipuncture and was used in a plaque reduction assay to 
determine HMPV neutralizing antibody titers as previously described (Williams et al., 
2005c). The median of triplicate values for % HMPV neutralization for each animal of 
each genotype were plotted as a function of log2-transformed serum dilution factor and 
analyzed in a sigmoidal dose response curve to determine IC50. Nasal turbinates (NT) 
and lungs were collected for analysis and tissue viral titers measured by plaque titration 
as previously described (Williams et al., 2005c). For histopathology, the left lung was 
removed and inflated with 10% buffered formalin, paraffin-embedded, stained, and 
analyzed using a formal scoring system in a group-blinded fashion by an experienced 
lung pathologist as previously described (Erickson et al., 2012). 
 
Generation of Bone Marrow Chimera. WT and IFNAR-/- mice were exposed twice to 5 
gy of radiation, with 4 hour rest in between treatments, from a cesium irradiator. Mice 
were housed in sterile conditions and their water was supplemented with 6.25 mg/mL 
Sulfamethoxazone and 1.25 mg/mL Trimethoprim. After 24 hours later, bone marrow 
was harvested from both WT and IFNAR-/- mice as previously described (Erickson et al., 
2014a), and 1x106 WT and 1x106 IFNAR-/- bone marrow cells were injected retro-
orbitally. Mice were rested for 8 weeks before HMPV infection. 
   
Flow Cytometry. Cells were isolated from lungs of infected animals as previously 
described (Erickson et al., 2012). Briefly, lungs were rinsed in R10 medium (RPMI-1640 
(Mediatech) plus 10% FBS, 2 mM glutamine, 50 µg/ml gentamicin, 2.5 µg/ml 
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amphotericin B, and 50 µM β-mercaptoethanol (Gibco, Invitrogen), and then minced with 
a scalpel and incubated with 2 mg/ml collagenase A (Roche) and 20 µg/ml DNase 
(Roche) for 1 hour at 37°C. Single-cell suspensions of digested lungs were obtained by 
pressing through a steel screen (80 mesh) and then passing over a nylon cell strainer 
(70-µm pore size). Erythrocytes were lysed using Red Blood Cell Lysis Buffer (Sigma-
Aldrich). For labeling of HMPV-specific CD8+ T cells, single cell suspensions of mouse 
lungs were incubated with APC-labeled H2-Db tetramers (0.1-1 µg/mL), anti-CD8α 
(clone 53-6.7, BD Biosciences), and anti-CD19 (clone 1D3, eBioscience) (Erickson et 
al., 2012). Surface/tetramer staining was performed for 1 hour at room temperature in 
PBS containing 2% FBS and 50 nM dasatinib (LC Laboratories) (Lissina et al., 2009). 
For assessment of PD-L1 expression, cells were stained with anti-EPCAM (clone G8.8, 
Biolegend), anti-CD11c (clone HL3, BD), anti-CD11b (clone M1/70, Tonbo), and anti-
MHC Class II (clone 2G9, eBioscience). Cells were also stained for PD-1 (clone J43, BD 
Biosciences), TIM-3 (clone RMT3-23), LAG-3 (clone C9B7W), 2B4 (clone m2B4 
(B6)458.1, Biolegend), PD-L1 (clone MIH5, BD), or an isotype control antibody (hamster 
IgG2κ). Staining for HMPV-specific CD8+ T cells was normalized to the binding of a 
cognate APC-labeled H2-Db tetramer loaded with NP366 flu peptide to CD8+ T cells 
(typically 0.05-0.2% of CD8+ T cells). For all cell populations FSC and SSC gating were 
used to obtain cells of appropriate size and shape. 
 
To identify HMPV-infected cell populations, homogenized lung cell suspensions were 
stained with polyclonal anti-HMPV guinea pig sera (Williams et al., 2005c) for 1 hour at 
room temperature (RT), washed, and then stained with an anti-guinea pig FITC 
secondary antibody (Life Technologies). Lung epithelial cells and CD11c+ high dendritic 
cells were identified using forward/side scatter and stained for EPCAM and CD11c as 
described above. Gates for HMPV-positive cell populations were set using uninfected 
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mice and isotype controls (BioLegend and BD). All flow cytometric data were collected 
using an LSRII or Fortessa (BD Biosciences) and analyzed with FlowJo software (Tree 
Star).   
 
Intracellular Cytokine Staining (ICS). Lung or spleen lymphocytes were isolated and 
re-stimulated in vitro for 6 hours at 37°C with a non-specific peptide or the indicated 
synthetic peptide (10µM final concentration) in the presence of an anti-CD107a antibody 
(clone 1D4B, BD Bioscience). The protein transport inhibitors brefeldin A and monensin 
(BD Biosciences) were added for the final 4 hours of re-stimulation. Stimulation with 
PMA/ionomycin (50ng/mL PMA and 2µg/mL ionomycin, Sigma) served as a positive 
control. After re-stimulation, cells were stained for surface expression of CD3ε (clone 
145-2C11), CD8α, and CD19, followed by fixation/permeabilization and staining for 
intracellular IFNγ (clone XMG1.2) (BD Biosciences) and were analyzed using flow 
cytometry. Background cytokine levels following re-stimulation were normalized to a 
non-specific peptide. 
 
Statistical Analyses. Data analysis was performed using Prism v4.0 (GraphPad 
Software). Groups were compared using unpaired t-test or one-way ANOVA with post-
hoc Tukey test for multiple comparisons. P <0.05 was considered significant by 
convention. 
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CHAPTER V 
 
Summary and Future Directions 
Thesis Summary 
 PRR detection and type I IFN signaling are conserved throughout the animal 
kingdom, and represent a significant negative pressure on the life cycle of viruses. 
These pathogens have evolved a myriad of innate immune evasion mechanisms to 
escape detection and response by the host, but the HMPV genome lacks homology for 
the known innate immune evasion genes in the Paramyxoviridae family. This thesis 
 
Figure 5-1. Model of type I IFN evasion effect on TCD8 response.  Respiratory epithelium 
is infected with HMPV, which induces signals through the detection of viral nucleic acids 
by PRRs to induce the expression of type I IFNs. These molecules can act in an 
autocrine and paracrine fashion to upregulate anti-viral peptides, cytokines and 
chemokines. As viral replication progresses the expression of the SH protein increases 
and is capable of downregulating signaling through the inhibition of STAT1. This in turn 
leads to increased viral replication in the infected cell, and higher levels of Ag stimulation 
of responding TCD8 cells inducing higher inhibitory receptor expression. Proximal APCs 
can interact with TCD8 via inhibitory receptor interactions and lead to functional 
impairment.    
 
SH	  SH	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uncovers a viral gene product from HMPV that is capable of inhibiting signaling through 
the type I IFN pathway by targeting STAT1, and elucidates potential repercussions of 
this evasion on the replication, pathogenesis and adaptive immune response in an 
animal model.  
 I first set out in this thesis project using a cell line derived from healthy bronchial 
epithelium, BEAS-2B, to determine the effects of HMPV infection on cells in vitro. 
Western blot, as well as bulk flow analysis, showed that BEAS-2B cells infected with 
HMPV upregulated STAT1, but were inhibited in their ability to undergo IFN-induced 
phosphorylation of this molecule. Curiously, when HMPV-specific antibodies were used 
to separately analyze both HMPV-infected and uninfected BEAS-2B cells in the same 
well, both groups were found to significantly upregulate STAT1 and become refractory to 
further IFN-induced STAT1 phosphorylation. Since we know that type I IFN is expressed 
at high levels in these cells upon activation of RIG-I, a known PRR for the detection of 
HMPV (Boehme and Compton, 2004; Manuse and Parks, 2010; Matsumoto et al., 2003; 
Melchjorsen et al., 2005; Rudd et al., 2005), and is capable of acting in an autocrine and 
paracrine fashion (Yoneyama et al., 2005), I wanted to investigate whether this 
expression and subsequent signaling in this cells could lead to this later observed 
inhibition.  
 By treating these cells for an extended period with type I IFN and also by 
inducing the endogenous expression of these molecules through the use of the synthetic 
viral nucleic acid, poly(I:C), I was able to show that this phenotype is induced by the 
detection of virus by PRRs and the ensuing type I IFN production during infection of this 
cell type and not by an HMPV-specific mechanism. These results indicate that cells 
capable IFN production are a poor system for the analysis of the phenomenon of innate 
immune evasion. Fortunately, HMPV is capable of infecting a cell line derived from the 
kidney epithelium of the African green monkey, Vero cells, and this cell line has a defect 
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in the production of type I IFN but not the recognition of viruses through PRRs or the 
signaling through the JAK/STAT pathway (Emeny and Morgan, 1979a; Hasler and 
Wigand, 1978). Long-term treatment of this cell line with IFN did not result in an 
upregulation of STAT1, and later treatment of these cells with IFN was sufficient to 
induce STAT1 phosphorylation. It is intriguing to consider, that lung epithelia in vivo most 
likely has a phenotype that more closely resembles that seen in the BEAS-2B cell line. 
This suggests that these cells have intrinsic mechanisms to quickly upregulate interferon 
stimulated genes (ISGs), and indeed recent work has shown that these cells have high 
basal levels of innate immune pathways (Seng et al., 2014). Previous work showing 
HMPV can inhibit IFNα, but not IFNγ, were performed in lung epithelial cell lines 
competent for type I IFN production so these findings might suffer from these 
confounding effects (Dinwiddie and Harrod, 2008). 
Using the Vero cell line and again utilizing an HMPV-specific antibody to label 
infected cells, I was able to show that infection of these cells with HMPV resulted in 
significantly lower expression level of STAT1. When these cells were treated with type I 
IFN, they also showed a significant decrease in their ability to phosphorylate STAT1. 
This time, the phenotype was not observed in the uninfected cells grown in the same 
well. This shows that HMPV has the capability to specifically affect the type I IFN 
pathway, but I was interested in which viral protein was responsible for this 
phenomenon. To that end, I went about generating overexpression plasmids of the 
HMPV viral proteins. 
In order to maximize the efficiency of translation for the viral proteins, we 
modified the viral gene sequences for optimal codon usage and GC content in 
mammalian cells (Graf et al., 2004). Next, with the help of Sherry Wen and Laura 
Peterson, I cloned these mammalian-optimized viral protein genes into overexpression 
plasmids for HMPV proteins, as well as GFP-fusion proteins of these viral gene 
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products. When the SH protein of HMPV was expressed in these Vero cells, reduced 
expression of the STAT1 protein was seen, and when treated with type I and II IFNs, 
these cells showed reduced STAT1 phosphorylation as compared to both mock-treated 
and cells in the same well. Other expression vectors, such as those for the N and P 
proteins, were able to drive high levels of viral protein in transfected cells, but the 
expression of SH was restricted to a lower level indicating that toxicity might occur at 
high expression levels. 
To further validate the effect of SH on STAT1, I also generated 293flp cell lines 
stably expressing HMPV proteins and measured STAT1 expression, phosphorylation 
and promoter activity downstream of the type I IFN pathway. I observed that the 
expression of SH in these cells for the multiple passages necessary for selection, 
resulted in a significant upregulation of STAT1 protein expression, possibly due to 
compensation over time in these cells. Despite this higher expression, when these cells 
were treated with type I IFN, less relative STAT1 phosphorylation was observed. By 
using a luciferase reporter plasmid driven by 6 copies of the ISRE promoter, I was able 
to show that the SH protein was also capable of blocking signals downstream of STAT1. 
Interestingly, when these cells were analyzed by forward and side scatter area they 
appeared larger in both measurements, perhaps showing that SH interacts with 
membranes of these cells and alters them. This would be reasonable in light of data 
indicating this protein may be capable of forming pores in the cell membrane (Masante 
et al., 2014). Taken together these data show that the SH protein of HMPV can 
downregulate signaling through the type I IFN by affecting STAT1 expression and IFN-
induced phosphorylation. Further work to elucidate the mechanism by which SH is able 
to evade innate immune signaling will be proposed later in this chapter.  
The preceding data has demonstrated that HMPV is able to inhibit type I IFN 
signaling, and inhibitory mechanisms employed by other viral pathogens to target this 
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same pathway is well described. This led me to ask what the implications of this evasion 
of the innate immune system were on the development of a strong adaptive response, 
and particularly a robust TCD8 response. In order to accomplish this, I requested a mouse 
line deficient in the receptor for type I IFN signaling, IFNAR, from Skip Virgin’s lab at 
Washington University in St. Louis. These mice were intranasally infected with HMPV 
and analyzed for viral replication and pathogenesis, as well as for the development of 
TCD8. I also examined the expression level of the inhibitory T cell receptors, PD-1, TIM-3, 
Lag3 and 2B4 on HMPV-specific TCD8 as well as the ligand for PD-1, PD-L1. 
I showed that early in infection, day 3 and 5, there was significantly more HMPV 
replication in the IFNAR deficient animals, but they were able to clear virus with normal 
kinetics. Intriguingly, while WT mice lost a small but significant amount of weight early in 
infection, this weight loss was not observed in IFNAR-/- mice. In order to measure 
disease pathogenesis in these mice throughout viral infection, I used a mouse pulse 
oximeter and showed that, corroborating the previous experiment, mice lacking IFNAR 
seemed to be significantly protected from increased breath distension, a measure of 
breathing effort. This indicates that instead of being necessary for clearance of HMPV, 
type I IFN signaling could do more to contribute to the morbidity of this virus. 
To further investigate whether type I IFN signaling was driving the disease state 
in these animals, I harvested lung tissue from WT and IFNAR-/- mice to analyze by 
histology. In WT animals a significant inflammatory infiltrate was observed during HMPV 
infection on day 5 compared to mock-infected mice, and this disease state was 
significantly ameliorated by ablation of the IFNα receptor. Expression of multiple 
inflammatory cytokines was also significantly higher in WT than in IFNAR-/- mice during 
HMPV infection when measured by RT-PCR, and IFNγ levels were significantly higher 
by ELISA. Recent work on RSV has shown a similar role for IFNAR in the upregulation 
of inflammatory cytokines. These data confirm the previous work suggest a role for type I 
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IFN signaling in the pathogenesis of HMPV, and also show the importance of this 
pathway in the robust development of an immune response. 
Neutralizing Ab levels have proven to be the key mechanism preventing 
reinfection of WT mice in vivo, and IFNAR-/- mice were shown in chapter III to generate 
protection from subsequent infection. The results in chapter IV showed that, in fact, 
serum from these IFNAR-deficient animals actually contained significantly more nAbs as 
measured by neutralizing plaque assay. This phenotype is likely due to increased viral 
antigen in these animals, but it is also possible that lack of type I IFN leads to a more 
Th2-type response, capable of producing a more potent nAb response. The total number 
of lymphocytes was not significantly different between uninfected and HMPV-infected 
WT or IFNAR KO mice, but both groups upregulated the number of CD11c+ cells during 
infection. Bulk CD8+ T cells were higher during HMPV infection in WT mice, but the 
IFNAR-/- mice did not show a difference in the number of TCD8 during infection. Since 
these cells are crucial for HMPV response, I wanted to also analyze the quality of the 
TCD8 virus-specific response using HMPV-specific tetramer molecules and intracellular 
cytokine staining. 
IFNAR-/- mice showed a significant defect in their ability to generate an HMPV-
specific TCD8 response. These results were not surprising since previous work has 
suggested that type I IFN is important in direct and indirect signals to these cells for their 
proliferation. What was more interesting was that these specific T cells were also less 
able to respond in a functional manner to peptide stimulation in the ICS assay. Previous 
studies have shown that impairment of lung TCD8 during HMPV infection is driven by the 
upregulation of the inhibitory receptor PD-1, which is not differentially expressed 
between WT and IFNAR-/- mice. I originally hypothesized that since this inhibitory 
receptor interacts with its ligand, PD-L1, which is driven by promoters downstream of 
IFN signaling, that these cells would actually be more functional instead of less. To 
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further explore this curious phenomenon, I examined the expression of PD-L1 on both 
lung epithelial cells and CD11c+ cells, which includes subsets of APCs discussed in 
more detail later. 
In order to specifically analyze the PD-L1 expression on infected lung epithelium 
I used a polyclonal HMPV-specific Ab to probe for HMPV-infected cells expressing the 
epithelial cell marker, EPCAM. Using this assay I showed that not only are levels of 
HMPV replication higher in IFNAR-/- mice, but more lung epithelial cells are infected in 
these animals. The level of PD-L1 was highest in infected WT cells on day 5, but this 
inhibitory ligand was also increased in infected animals in the absence of type I IFN 
signaling indicating that IFNAR is sufficient but not necessary for the upregulation of PD-
L1 on these cells. It should also be noted that infected cells in both WT and IFNAR-/- 
mice more highly expressed PD-L1 than the uninfected EPCAM+ cells from the infected 
mouse, showing that signaling within the infected cell is also capable of increasing the 
levels of the inhibitory ligand. By day 10, the percentage of PD-L1 expressing lung 
epithelial cells was greatly reduced and no difference was seen between groups. The 
baseline percentage of PD-L1 expressing CD11c+ cells was markedly higher than the 
lung epithelium, but only a slight, non-significant, increase in these cells was seen at day 
5 post-HMPV infection and this difference disappears by day 10. 
Since the expression of IFNAR results in higher PD-L1 expression, as expected, 
the interactions between PD-1 and PD-L1 do not appear to drive the difference in 
functionality detected between WT and IFNAR-/- animals. CD4+ Tregs are also capable 
of exerting inhibitory actions on TCD8. Recent data from an LCMV model indicates that 
direct type I IFN signaling on Tregs can suppress proliferation (Srivastava et al., 2014a), 
but other groups have shown that this signaling can also play a role in FOXP3 
maintenance and the development of the suppressive phenotype of this subset of T cells 
(Lee et al., 2012). Interestingly, in our disease model IFNAR-/- mice displayed a 
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significant defect in the number of these cells present in the lung during HMPV infection, 
failing to provide an explanation for TCD8 impairment. Other inhibitory receptors besides 
PD-1 can also contribute to the impairment of TCD8 in the lungs, so I next measured the 
percentage of HMPV-specific T cells that expressed the inhibitory receptors, 2B4, Lag3 
and TIM-3. While no difference was observed between WT and IFNAR KO animals 
during viral infection for 2B4 or Lag3 expression, the percentage of HMPV-specific TCD8 
cells expressing TIM-3 was significantly higher in mice deficient for type I IFN signaling. 
These data indicate a possible mechanism through the action of the inhibitory receptor 
TIM-3 for impairment of the TCD8 in the absence of type I IFN signaling.  
The CD11c+ population analyzed previously contains multiple subsets of APCs, 
and I wanted to further explore the expansion and PD-L1 expression in each of these. 
Using a multi-parametric flow gating scheme I was able to distinguish five separate 
subsets of APCs in the lungs, alveolar macrophages, interstitial macrophages, 
plasmacytoid DCs, CD11b+ DCs and CD11b- DCs. I measured both the expansion of 
these cells in the lung compartment during HMPV infection, as well as the PD-L1 
expression in naïve and HMPV-infected mice.  
Alveolar macrophages represented the largest subset of APCs in the lungs of 
both WT and IFNAR-/- mice at day 5 post-infection, and IFNAR-deficient animals actually 
had a higher number of these cells as compared to WT during infection. This shows that 
the expansion of these cells occurs independently of type I IFN signaling. Interstitial 
macrophages and the three subsets of dendritic cells on the other hand, were 
significantly lower in IFNAR-/- mice during HMPV infection indicating that these cells 
require type I IFN for their proliferation or infiltration to the lung early in viral infection. I 
wanted to know if these cells had varying degrees of suppressive capabilities towards 
TCD8, so I measured PD-L1 levels in the subsets of APCs in the lung. 
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The baseline expression level of PD-L1 was found to be strikingly different 
between these groups of APCs. Alveolar macrophages were found to constitutively 
express PD-L1 even in uninfected mice, while the percentage of dendritic cells and 
interstitial macrophages expressing PD-L1 in uninfected mice was much lower. For 
interstitial macrophages, the number of PD-L1 expressing cells at steady state was also 
dependent on type I IFN, as IFNAR-/- mice had significantly less than their WT 
counterparts in uninfected mice. Type I IFN signaling was also shown to be crucial for 
the increase in PD-L1+ cells in the subsets beside alveolar macrophages. IFNAR-/- mice 
did not show an increase in PD-L1+ interstitial macrophages or dendritic cells at day 5 
post-HMPV infection. When the level of expression of PD-L1 was measured on cells 
expressing this inhibitory ligand, it became even clearer that type I IFN is important for 
the upregulation of PD-L1. In every subset of APC found in the lung, the expression of 
PD-L1 was higher in infected IFNAR-competent animals than uninfected controls, and 
this increase in expression was lost in IFNAR-/- mice. I also showed that alveolar 
macrophages expressed significantly higher levels of the inhibitory ligand on PD-L1+ 
cells than in pDCs, CD11b+ and CD11b- DCs, as well as interstitial macrophages. These 
data indicate that alveolar macrophages may represent a subset of APC that is 
particularly capable of the inhibition of TCD8 response in the lungs. Since the increase in 
was not dependent on type I IFN signaling, the ratio of PD-L1hi alveolar macrophages 
compared to the other PD-L1lo APC subsets was increased in IFNAR-/- mice. This 
difference could contribute to higher levels of impairment observed in these mice, as 
more TCD8:APC interactions occurred between the T cells and this PD-L1hi population of 
APC as compared to other subsets, perhaps more capable of generating a functional 
response. 
At day 10, I showed that signals other than type I IFN results in an increase in 
many APC subsets, as well as potent upregulation of PD-L1 on conventional DC 
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subsets. This is most likely due to type II IFN signaling by T cells responding to HMPV 
infection, and shows the benefit for a virus in targeting a component present in both 
pathways such as STAT1. I also observed that conventional DCs have two distinct 
expression levels of PD-L1, and the ratio of high PD-L1 expressing to low PD-L1 
expressing CD11b- DCs is much higher than CD11b+ DCs. This suggests that, as has 
been suggested (Kim and Braciale, 2009), CD11b- DCs are more capable at driving a 
functional response and this proximity to highly functional TCD8 leads to an upregulation 
of this inhibitory molecule. 
Finally, in order to investigate the importance of type I IFN signaling on 
hematopoietic compared to non-hematopoietic cells, I generated reciprocal bone marrow 
(BM) chimeras of WT and IFNAR-/- mice. Preliminary data from these experiments show 
that the lung dysfunction observed during HMPV infection in WT mice is driven by type I 
IFN signaling in both compartments, since neither mice with IFNAR-/- tissue nor those 
with IFNAR-/- BM displayed as severe pathogenesis as the WT animals, as measured by 
breath distension. The functionality and magnitude of the TCD8 response, in contrast, was 
driven by type I IFN signaling on BM-derived cells. HMPV-specific TCD8 was greater in 
WT and mice with WT BM but IFNAR-/- tissue, as compared to either holistic IFNAR KO 
or mice reconstituted with IFNAR-/- BM.  
The data presented in this thesis contribute to the understanding of how the 
innate immune system is able to prime a functional anti-viral response to respiratory 
viruses and what the implications of type I IFN signaling are on disease pathogenesis. 
Chapter II also outlined a potential mechanism for type I IFN evasion for HMPV via the 
expression of the SH protein and its inhibition of STAT1. My data reveal that type I IFN 
signaling in the tissues of the lung make a significant contribution to disease 
pathogenesis during HMPV infection, and that without this IFNAR signaling in BM-
derived cells, the infected host is unable to generate as potent of an anti-viral TCD8 
 104 
response. Despite this, IFNAR-/- mice are able to clear HMPV with normal kinetics, 
suggesting that, for critically ill patients, a therapeutic approach targeting the type I IFN 
response might actually lead to less disease. It will be important to closely study the 
consequences of loss of type I IFN signaling in repeat infections, but data presented 
here show that mice lacking this pathway are able to potently develop a nAb response 
required for protection. Overall, the results presented in this thesis suggest that the 
evasion of type I IFN by HMPV results in higher viral replication and less disease, 
without affecting viral clearance, representing a distinct evolutionary advantage to the 
virus. 
 
Figure 5-2. Heterogeneous APC populations in the lung upon HMPV infection. The ratio 
of PD-L1 high alveolar macrophages to other APC populations with lower PD-L1 
expression is increased in the absence of type I IFN signaling on day 5, but APC ratios 
are similar at day 10 although overall APC numbers are markedly increased. 
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Future Directions 
 
Mechanisms used by HMPV SH protein to inhibit STAT1 
 While evidence in this thesis shows that HMPV can use the expression of the SH 
protein to inhibit STAT1 expression and phosphorylation (Chapter II), the mechanism by 
which this viral protein exerts its inhibitory action is unknown. As discussed earlier, 
paramyxoviruses use various specific mechanisms to target STAT1, but virtually all 
require a physical interaction with the host molecule (Andrejeva et al., 2004; Childs et 
al., 2012; Gainey et al., 2008; Lo et al., 2005). Therefore, it will be interesting to generate 
an HA- or FLAG-tagged overexpression plasmid of the SH protein to perform IP pull-
down assays in vitro, and explore what cellular factors might interact with this protein. 
Since this interaction could be transient, a technique developed to increase sensitivity of 
pull-downs between labile binding partners by temporarily cross-linking the interacting 
proteins together before precipitating the protein complex, called reversible cross-link 
immuno-precipitation (ReCLIP), could be used (Smith et al., 2011). 
 In order to analyze the cellular factors potentially interacting with the SH protein, 
we will first run the IP product on a SDS-PAGE gel and use specific antibodies towards 
components in the type I IFN pathway, including STAT1, to probe for their presence. 
This same gel can also be probed with coomasie to non-specifically label proteins, and 
individual bands differing from controls can be excised from the gel and subjected to 
shotgun analysis by single-dimension liquid chromatography tandem mass spectrometry 
(LC-MS/MS) (Smith et al., 2011). The importance of these identified SH binding partners 
to STAT1 inhibition can then be assessed by using siRNAs to specifically target these 
proteins.  
 Once cellular targets of the SH protein are identified, the domain with which this 
protein interacts with its target should be determined. Since HMPV SH is a type II 
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transmembrane protein, its N-terminus is thought to be embedded in the membrane, so 
by progressively deleting the C-terminal tail the motif necessary to interact with host 
proteins can be identified. SH is also thought to contain multiple N-glycosylation sites so 
the mutation of these sites will allow us to determine if the glycosylation of SH 
contributes to its function as an innate immune antagonist. The SH protein of HMPV is 
only about 60% conserved among the subgroups of this virus (Biacchesi et al., 2003; 
van den Hoogen et al., 2002), and so far only the version from the A2 subgroup has 
been analyzed. To determine if this affect is conserved, overexpression plasmids with 
the SH protein from the A1, B1 and B2 subgroups of HMPV should be generated and 
tested in these assays. 
 Many paramyxoviruses hijack cellular proteasomal pathways to degrade 
important innate signaling molecules (Andrejeva et al., 2002; Ramaswamy et al., 2004; 
Ramaswamy et al., 2006), but preliminary studies using an irreversible proteasome 
inhibitory, epoxomicin, indicate that chemical inhibition of the proteasome does not 
prevent that inhibition of STAT1 (data not shown). Additional work to further test this 
pathway, perhaps using other proteasome inhibitors or testing a wider concentration of 
epoxomicin, is necessary to completely eliminate the possibility that SH is using host 
proteasome to apply its inhibitory action on STAT1.  
 Microscopy can be used to determine the sub-cellular localization of both the SH 
protein, as well as STAT1, and to determine if these two molecules co-localize together. 
Other paramyxoviruses have shown the capability to sequester STAT1 in high molecular 
weight conglomerates (Rodriguez et al., 2004; Rodriguez et al., 2002), and both the 
transient SH-GFP overexpression plasmid as well as the stably transfected 293Flp cell 
line expressing HMPV-SH can be used to assess the effect of SH on STAT1 in vitro. 
Other groups have suggested that HMPV SH, like RSV SH, can form a viroporin 
(Masante et al., 2014), and these studies could shed more light on how this putative 
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function might harmonize with the ability for this protein to inhibit STAT1. Finally, the use 
of the HMPV-ΔSH virus can be used along with expression plasmids of SH mutants to 
determine if these mutants can rescue wild-type function, and this virus can also be used 
in vivo to look at the generation of adaptive immune responses. 
   
Importance of IFNAR signaling in various immune cell types for TCD8 function and 
HMPV pathogenesis   
Experiments outlined in chapter IV began to answer the question of which cell 
type relies on type I IFN signaling for its part in the generation of a robust and functional 
T cell response. I generated reciprocal bone-marrow chimeras of WT and IFNAR-/- mice 
to create mice that expressed the type I IFN receptor only on hematopoietic cells or only 
in non-hematopoietic cells, and infected them with HMPV to determine how expression 
in each of these host compartments affects HMPV pathogenesis and T cell response. 
The results can be found previously, but, in short, type I IFN signaling in bone-marrow 
derived cells is particularly important for the generation of a specific functional TCD8 
response. Deletion of INFAR in either cell type ameliorates disease pathogenesis as it is 
measured by lung dysfunction, in a phenomenon likely related to the expression of type 
II IFNs. 
 In order to more accurately deduce the effect of type I IFN deficiency in 
hematopoietic or non-hematopoietic cells, it will be important to monitor the kinetics of 
viral replication in these animals. IFNAR-/- mice showed higher replication early in HMPV 
infection but normal clearance, and titers should be measured in bone-marrow chimeric 
mice over the course of a normal infection. I hypothesize that type I IFN in the lung 
tissue plays an important role in early HMPV replication, and that this higher early 
replication leads to higher nAb response, since viral antigen drives the neutralizing 
response (Pinschewer et al., 2004), and enhanced clearance as lower PD-L1 and higher 
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Ag levels early in infection drive a functional response. The presence of APCs in the 
lungs of mice infected for 10 days with HMPV in these animals is difficult to interpret 
given the extensive overlap in downstream signaling events between type I and type II 
IFN (Platanias, 2005), so an analysis of these cells at day 5, before substantial TCD8 
infiltration and IFNγ expression, is needed. 
 The reconstitution of IFNAR-/- mice with bone marrow from WT animals can 
restore TCD8 function, but this assay cannot parse the contribution of type I IFN signaling 
to impairment in individual cell types within this group. Published data shows that type I 
IFN signaling directly on TCD8 could be important for the development of a strong T cell 
response (Kolumam et al., 2005b), and also that IFNAR signals are crucial for the 
proliferation and maturation of APCs, important for a potent TCD8 response. To determine 
the direct contribution of type I IFN signaling in TCD8 cells, CD8-Cre (Yao et al., 2013) 
expressing mice can be bred with IFNARflox/flox mice to generate a mouse lacking IFNAR 
specifically on CD8+ T cells and the response to intranasal infection with HMPV should 
be monitored. To more closely examine the importance of this signaling in the APC 
subsets, CD11c-Cre (DCs/Alveolar Macs) (Caton et al., 2007) or LysM-Cre 
(Macrophages) (Clausen et al., 1999) can be used with the IFNARflox/flox mouse strain to 
ablate expression of IFNAR on these cells. Subsets of APCs can also be harvested from 
WT and IFNAR-/- mice at the peak of HMPV infection and used in ex vivo T cell 
activation assays to see if these cells have a differential capacity to prime a functional 
TCD8 response (Kim and Braciale, 2009). 
 Since we know that type I IFN signaling can play an important role in early 
immune development, it would be ideal to have a model that developed in a normal 
manner but then could be manipulated temporally to lose expression of IFNAR. The 
newly developed CRISPR-Cas9 technology allows for just that. Recently, a mouse has 
been developed on the C57BL/6 background that constitutively expresses the Cas9 
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enzyme in all cells, as well as one expressing this enzyme upon Cre-expression (Platt et 
al., 2014). These mice will also both soon be available through Jackson laboratories. It 
was shown that by utilizing short-guide RNAs (sgRNA) specific for a gene sequence 
they were able to efficiently ablate genes even in difficult to target primary cells, like 
dendritic cell precursors in the bone marrow (BMDCs)(Platt et al., 2014). The Cas9-
expressing cells also express EGFP, which allows for easy identification of these cells 
upon transfer to a second animal.  
To determine what the role of IFNAR is on specific cells, the CD8-Cre, CD11c-
Cre and LysM-Cre mice could be used in conjunction with the Cas9 mouse to generate 
mice expressing the enzyme necessary for excision of the gene only in specific cell 
types. Next, a lentivirus could be injected into mice to transduce the IFNAR sgRNA into 
cells in vivo (Leander Johansen et al., 2005). This would result in a specific loss of 
IFNAR only in cells expressing Cre, and then HMPV infection of these mice could be 
used to determine the specific contribution of type I IFN signaling in selected cells to the 
overall host response. Alternatively, a technique for generating lentiviral vectors capable 
of targeting specific cell types in vivo (Yang et al., 2006) could be used along with Cas9 
mice to transduce only specific cells in the immune response with the targeting IFNAR 
sgRNA. To target IFNAR in lung epithelial cells, an adenoviral vector could also be 
administered intranasally to deliver sgRNA to lung epithelium (Platt et al., 2014).  
Another attractive aspect of this experimental approach is that, it will allow us to 
probe the importance of IFNAR on the secondary response by first infecting with HMPV 
and then waiting until mice have developed immunity before experimentally manipulating 
animals to selectively delete the IFNAR receptor. In order to more accurately study the 
secondary response in vivo, a modification to our infection protocol is needed and that is 
explored more in the next section. 
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Generation of memory TCD8 in absence of IFNAR 
 As shown in chapter III, C57BL/6 mice, regardless of their expression of IFNAR, 
are capable of generating a potent neutralizing antibody response that results in 
protection from subsequent viral infections (Graham et al., 1991; Prince et al., 1999; 
Williams et al., 2005c). Because of this, these animals are of limited use for the 
examination of a memory response, but Blimp-1 and Bcl-6 are markers for effector and 
central memory, respectively, and a transcriptional analysis of WT compared to IFNAR-/- 
HMPV-specific TCD8 could compare the ratio of expression of these distinct drivers of 
differentiation and the give a clue as to whether a lack of type I IFN signaling drives the 
T cell response towards a more effector or memory phenotype.   
 To more fully characterize the secondary responses of TCD8 to HMPV, and the 
impact that type I IFN has on this reactivation, a mouse deficient in B cells, µMT, has 
been utilized in our lab to investigate secondary HMPV infection. These mice, while 
susceptible to re-infection with HMPV, are severely immunocompromised and could 
have secondary defects due to their complete lack of B cells (Kitamura et al., 1991). 
Therefore, I propose to instead use a mouse with a transgenic B cell receptor restricted 
in specificity to a single antigen, such as the model frequently used to study B cell 
immune tolerance which only makes antibodies specific to hen egg lysozyme (HEL) 
(Ferry and Cornall, 2004). These animals would be unable to make an HMPV-specific 
nAb response, but would have a more normal immune response as compared to µMT. 
These animals could be crossed with IFNAR-/- mice, either genetically or using bone-
marrow chimeras since my data shows that type I IFN in hematopoietic cells drives TCD8 
functionality, to assess the implications of type I IFN on the generation of a protective 
secondary TCD8 response and the impairment observed during viral infection.  
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Role of PD-L1high alveolar macrophages in TCD8 exhaustion and HMPV 
pathogenesis 
 Data presented in chapter IV of this thesis indicate that alveolar macrophages 
are the most abundant APC found in the lungs of naïve or HMPV-infected mice, and that 
they constitutively express the inhibitory ligand PD-L1. This raises the possibility that 
alveolar macrophages act as master inhibitory cells early in viral replication and could 
contribute to the TCD8 impairment observed during acute viral LRI. A recent study in 
influenza shows that the treatment of mice intranasally with clodronate-loaded liposomes 
can potently eliminate airway macrophages, and this leads to higher pathogenesis 
during viral infection (Tate et al., 2010). 
 Viral control, disease pathogenesis and TCD8 response should be measured in 
the context of macrophage depletion, as well as the ability for these animals to develop 
sterilizing immunity. Utilization of LysM-Cre mice and PD-L1flox/flox mice (Keir et al., 2007) 
to generate mice lacking expression of PD-L1 solely on macrophages could also be 
used to determine whether this cell type is a major contributor to the inhibitory effect on 
TCD8 in the lung. Using this macrophage-specific KO of PD-L1 and also a CD11c-Cre 
and PD-L1flox/flox breeding strategy to create mice lacking this molecule on both alveolar 
macrophages and dendritic cells could provide a good way to determine whether these 
APC subsets have differential or overlapping roles in TCD8 impairment over the course of 
HMPV infection.  
 
Conclusions and significance  
 Together, the data generated during my thesis work build a foundation that 
provides for multiple avenues for future studies. The molecular tools I have created can 
be used to evaluate the contribution of viral proteins from HMPV on a myriad of cellular 
processes, and the flow assays I have designed will allow for the further analysis of the 
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various APC subsets in vivo during acute respiratory viral infection. The future directions 
outlined here will elucidate the mechanism underlying the observed inhibition of STAT1 
signaling by the SH protein of HMPV. Additionally, these experiments will enrich the 
understanding of the role of type I IFN signaling on individual cell types involved in the 
TCD8 response in the lungs during acute viral infection. They will also specifically 
examine the inhibitory role of alveolar macrophages in the lung during acute viral 
infection, as well as their contribution to disease pathogenesis. These studies will help to 
uncover more about the specific immune evasion strategy of HMPV. They will also aid in 
furthering our understanding of the contribution of the balance of APC subtypes in the 
lung to TCD8 impairment and pathogenesis during HMPV. The ability for HMPV to reinfect 
individuals, despite the presence of neutralizing antibodies, is a major public health issue 
and the presence of alveolar macrophages, with a potent ability to inhibit TCD8 response, 
could increase the likelihood of this occurrence. Understanding the importance of the 
type I IFN response in pathogenesis could also lead to the development of improved 
therapies for severely ill patients. 
 The type I IFN response is crucially important for the response of the host to 
some viruses, and loss of this pathway leads to lethal consequences in these models. 
For HMPV however, the loss of type I IFN signaling, while leading to significantly more 
viral replication early in infection, is not catastrophic for the infected animal. The data 
presented in this thesis suggest that this is likely due to an overlapping role between 
type I and II IFN in the anti-viral response. HMPV has responded to this dual-attack 
stratagem of the host by evolving strategies that target STAT1, a molecule common to 
both signaling pathways. This allows for the virus to replicate to higher levels locally in 
infected cells while the IFN pathway drives disease pathogenesis, which actually 
facilitates the expulsion of viral particles from the lung through coughing. The ability for 
the adaptive response to clear this virus without assistance from type I IFN signaling, 
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reveals this pathway as one that potentially could be therapeutically manipulated to 
ameliorate symptoms in the lungs of patients severely ill with HMPV without 
repercussions to clearance.  
 In light of my data showing the IFN-induced pathogenesis of HMPV, the 
phenomenon of Ag-driven TCD8 impairment in the lungs during acute viral infection can 
be seen as a host adaptation to protect the sensitive and crucial tissues of the lung. An 
over-active TCD8 response can be detrimental to the host, and even the highly impaired 
function observed in virus-specific TCD8 in IFNAR-/- mice is sufficient to clear HMPV. The 
implications of this impairment to the memory response could lead to significant 
advancements in vaccine development and to the understanding of why viruses like 
HMPV are able to repeatedly infect individuals despite the presence of neutralizing 
antibodies.  
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